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PREFACE  
This thesis is the result of a PhD project under the supervision of Professor Birte Svensson at 
DTU and Kim Henriksen Ph.D. at Nordic Bioscience. Furthermore, Professor Susanne Jacobsen, 
Associate Professor Per Hägglund at DTU and Anders Nedergaard, PhD at Nordic Bioscience 
acted formerly as supervisors in the project. All the experiments were conducted at Nordic 
Bioscience, Herlev, Denmark from January 2014 to August 2017.  
This work includes an introduction to the field and current relevant topics, in addition to the 
laboratory work performed in three clinical studies, as described in the included manuscripts. 
In the discussion section the different aspects of the experimental work are presented and 
discussed in line with relevant literature, concluding with limitations and possible future steps. 
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ABSTRACT 
 
Muscle protein turnover is a dynamic equilibrium that regulates the body composition and 
homeostasis through various cytokines and proteases. When the balance between protein 
synthesis and protein degradation is altered, proper muscle function and regeneration is being 
hampered, affecting patient’s quality of life. In these conditions, a constellation of symptoms 
as inflammation, fibrosis and muscle wasting has been widely observed despite different 
onsets. Many of these pathologies are incurable and can only be treated symptomatically.  
A wide array of biomarkers has been used to monitor qualitative and quantitative changes in 
muscle. Unfortunately, there has not been an ideal panel of biomarkers that can be readily 
applied in studies and assist with prognosis of the disease or response to treatment. Protein 
biomarkers in serum are easily obtainable, not as invasive as other methods and can be used 
as targets for sensitive antibody-based assays. 
The overall hypothesis is that both the ECM and myofibrillar biomarkers are released in 
circulation of people with muscle pathologies and can be used to develop bioassays. We 
wanted to test if those protein fingerprint biomarkers can characterize and distinguish between 
healthy individuals and patients with different myopathy diseases, describe the underlying 
mechanisms of muscle conditions and possibly putative response to an intervention. There 
were three different studies where biomarkers were applied in this thesis.  
 
Study I involved 51 myositis patients (28 Dermatomyositis, DM and 23 Polymyositis, PM) 
compared to a control group. A range of biomarkers derived from cleavage of collagens I (C1M 
and PINP), III (C3M and PRO-C3), VI (C6M) and C-reactive protein (CRPM) was applied to 
distinguish between the diseases in this cross-sectional cohort. Both DM and PM significantly 
affect several of the biomarkers levels measured in this study, most prominently CRPM and 
PINP, indicative of significantly altered turnover of extracellular matrix components and CRPM.  
C3M correlated with Interferon gene score, in PM and DM, and CRPM with MMT8 score in DM.  
 
We further developed an assay directed at the C-terminal of troponin T1 (TNNT1) that was 
measured in studies II and III.  
In study II, a group of cancer patients after radiotherapy was admitted to a resistance-training 
program alongside to a control group that followed the same training regime. Serum samples 
were obtained right after radiotherapy, before and during the training period. TNNT1 levels 
were significantly elevated in the patient group compared to the control group, even before 
engaging in any form of physical activity. After engaging in physical training, the biomarker 
levels further increased through time, reaching a significant difference both compared to the 
patients baseline (T24vsT0, p<0.05 ) as well as to the control group (T1 and T24 vs control, 
p<0.0001). 
 
In study III, healthy subjects were put in 56 days of bed rest, split in a group with resistance 
vibration exercise as a countermeasure and a group with no countermeasure at all. After the 
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bed rest period, both groups entered the same rehabilitation process for a period of 128 days. 
There was a significant difference between  the two groups in the bed rest stage that 
demonstrates a distinct response to the RVE counter measure.  The increased levels of 
circulating TNNT1 for the RVE group in this study could be explained by the unloading of 
troponin from the muscle.  During the remobilization stage, the TNNT1 levels were increased 
significantly in both groups in a very similar manner, compared to the baseline as well as the 
levels during the bed rest period. In day 28 of recovery were the maximum levels of TNNT1 
observed and by the time of training completion, the levels were almost returned back to 
baseline.  
 
The results of this thesis point to the fact that that a panel of biomarkers could fill in the need 
to characterize complex processes in rare neuromuscular diseases. Addressing the main 
manifestation of the diseases in well-described clinical cohorts could expedite pharmaceutical 
trials and provide valuable information on the pathology of the disease.  
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DANSK RESUMÉ 
Muskel protein turnover er en dynamisk ligevægt der regulerer kropssammensætningen og 
homeostase gennem cytokiner og proteaser. Når ligevægten mellem proteinopbygning og 
proteinnedbrydning bliver forskudt, medfører dette en hæmning af muskel funktion og 
regenerering, hvilket påvirker livskvaliteten for det enkelte individ. Uafhængigt af årssagen til 
denne lidelse, er der hos patienterne en kombination af symptomer såsom inflammation, 
fibrose og tab af muskelmasse. Flere af disse patologiske ændringer er uhelbredelige, og 
patienterne modtager primært symptombehandling. 
Et bredt panel af biomarkører blev benyttet til at måle kvalitative og kvantitative ændringer i 
musklerne. Dog er der på nuværende tidspunkt ikke udviklet et ideelt panel af biomarkører 
som kan benyttes til udvikling af lægemidler, forudsige progression af sygdommen eller 
registrere respons på en given behandling. Protein biomarkører i serum er let tilgængelige, 
non-invasive og kan benyttes som mål for sensitive antistof-baserede assays. 
Hypotesen i denne PhD afhandling er at både extracellulær matrix (ECM) og myofibrillære 
proteinfragmenter bliver udskilt i blodbanen hos individer med forskellige muskel sygdomme. 
Disse fragmenter kan benyttes til udvikling af bioassays. Hvorvidt disse forskellige fragmenter 
(protein fingeraftryk) kan karakterisere og skelne mellem raske individer og patienter med 
forskellige myopatier, beskrive den underliggende mekanisme af muskel sygdommen eller 
respons på en given intervention, vides endnu ikke. 
Tre forskellige studier blev målt til evaluering af biomarkører i forbindelse med dette projekt. 
Studie I bestod af 51 myositis patienter (28 dermatomyositis (DM) og 23 polymyositis (PM)) 
sammenlignet med en kontrol gruppe. Forskellige biomarkører af kollagen type I (C1M og 
PINP), III (C3M og Pro-C3), VI (C6M) og C-reaktivt protein (DRPM) var målt, for at undersøge 
hvorvidt disse kunne skelne mellem DM, PM og kontrol gruppen i et tværssnitsstudie. I både 
DM og PM blev ændrede biomarkør niveauer detekteret i sammenligning med kontrollerne. 
Hvoraf de bedste markører CRPM og PINP indikerede en signifikant ændring i proteinturnover 
af ECM komponenter. C3M korrelerede med Interferon gen-scoren, i PM og DM, og CRPM 
med MMT8 scoren i DM, hvilket indikerer en potential anvendelse af disse markører i 
fremtidige studier af interventioner i PM og DM. 
Ydermere udviklede vi et assay rettet mod C-terminalen af troponin T1 (TNNT1), dette assay 
blev målt i studie II og III. 
Studie II bestod af en gruppe cancer patienter, som modtog strålebehandling og herefter blev 
inkluderet i et træningsprogram sideløbende med en kontrolgruppe. Serum prøver blev 
opsamlet umiddelbart efter strålebehandlingen før og under træningsperioden. TNNT1 
niveauet var signifikant forhøjede i patient gruppen i forhold til kontrol gruppen, før 
påbegyndelse af fysisk træning. Efter fysisk træning var niveauet af biomarkøren yderligere 
forhøjet, hvilket resulterede i en signifikant forskel sammenlignet med både patienter ved 
påbegyndelsen af studiet (T24vsT0, p<0.05) og kontrol gruppen (T1 og T24 vs kontrol gruppen, 
p<0.0001). 
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Studie III bestod af raske individer som var sengeliggende i 56 dage, og inddelt i to grupper 
hvoraf den ene udførte modstands vibrations træning (RVE) og den anden ikke udførte 
træning. Efter at være sengeliggende deltog begge grupper i den samme rehabiliterings 
proces i 128 dage. Der var en signifikant forskel mellem de to grupper som var sengeliggende, 
hvilket demonstrerer et forskelligt respons til RVE counter målingen. Det forhøjede niveau af 
TNNT1 i blodet for RVE gruppen i dette studie skyldes frigivelse af troponin fra musklen. I 
forbindelse med remobiliseringen af patienterne var TNNT1 niveauet forhøjet signifikant i 
begge grupper, sammenlignet med påbegyndelsen af studiet og gennem perioden hvor 
individerne var sengeliggende. Det højeste niveau af TNNT1 var observeret på dag 28 efter 
genoptræningen, hvorefter niveauet ved afslutningen næsten var normaliseret til det samme 
niveau som ved påbegyndelsen af studiet. 
 
Resultatet af dette projekt viser at et panel af biomarkører kan benyttes til at imødekomme 
behovet for karakteriseringen af processerne i sjældne neuromuskulære sygdomme. 
Sammenhængen mellem disse biomarkører og primære manifestationer af sygdommene bør 
karakteriseres i velkarakteriserede kohorter. Dette ville kunne bidrage til at validere 
biomarkørernes egenskab til at reflektere sygdommens patologi, og derfor om de ville kunne 
bruges i farmaceutiske studier som forsøger at påvirke disse mekanismer. 
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ABBREVIATIONS 
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1. BACKGROUND  
 
 
Skeletal muscle consists of aligned myofibers, which are multinucleated myocytes. Within each 
myocyte lies an organized bundle of contractile proteins that is collectively named as the 
sarcomere. The sarcomere comprises thin and thick filaments, which are responsible for muscle 
contraction. Main constituents of the thick filament are the light and heavy myosin chains. On 
the thin filament, actin monomers create a functional scaffold on which troponins and 
tropomyosin reside and take part of the regulation of muscle contraction 1–3. Larger proteins 
as titin, nebulin and obscurin form a structure that aligns the sarcomere and provide tension 
and elasticity 4.  
 
Myofibers can be further classified into two different types, depending on expression of 
different myosin heavy chain isoforms. The two groups are known as type I and type II 
myofibers or slow-twitch and fast-twitch fibers 5. Type I muscle fibers express type I myosin and 
are producing energy in a slow rate, through oxidative phosphorylation. Due to a higher protein 
synthesis and a higher oxidative capacity 6, there is a distinctively higher protein turnover rate 
in slow fibers7. Conversely, type II fibers express type II myosin, produce energy in rapid bursts 
and express metabolic enzymes favoring glycolytic/anaerobic metabolism. Type II fibers 
generate more power while type I fibers are favored in long activities that require endurance.  
 
Force is generated through muscle fiber contraction as regulated through the tropomyosin and 
troponin complex that resides on the thin filament. The troponin complex is composed by three 
different troponins: TnI, TnC and TnT, each serving different functionalities. TnC binds calcium 
ions and activates a conformational change that makes the inhibitory protein TnI to reveal the 
myosin binding sites on the actin filament, which enables muscle contraction. TnT serves as the 
anchor of the whole troponin complex by binding to tropomyosin and the other troponins 
through the C-terminus. The calcium-dependent muscle contraction is inhibited by TnT by 
suppressing myosin ATPase activity inactivating fiber contraction. Mutations in TnT can cause 
cardiomyopathies or nemaline myopathy which is a rare congenital muscle disease 
characterized by general weakness and hypotonia8. Complete absence of troponin T diminishes 
the Ca2+ dependent activation, while deletions in the last 14 or 28 amino acids in the C-terminus 
lead to ATPase activity 9. Irrespectively to presence of Ca2, truncation of the C-terminus 
prohibits full muscle relaxation10. Presence of slow skeletal troponin T in serum can reflect 
training-induced changes in muscle and more specifically the troponin complex or preferential 
modification caused in slow-twitch fibers. Exercise-induced damage has been shown to allow 
release of skeletal troponin I into the blood stream11. 
Muscle fibers are ensheathed in a cell membrane called the sarcolemma, which is the 
basement membrane and is mainly comprised of type VI collagen, dystroglycans, agrin and 
laminins. The basement membrane is attached to the fiber cytoskeleton via transmembrane 
proteins as dystrophin and integrins. It is further surrounded by the endomysium which is a 
layer of type III and IV collagen, further associating with collagen V12. The endomysium 
constitutes the inner part of the extracellular matrix (ECM) in the muscle, occupying the space 
between the sarcolemma of adjacent muscle fibers. Furthermore, the basement membrane 
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adjacent to the sarcolemma is mostly consisting of type IV and VI collagen13,14. Often times in 
literature, there is no distinction between the basement membrane and the sarcolemma. 
Fibers are further organized in bundles called fascicles and are further surrounded by an ECM 
layer called perimysium. Collagen type I dominates the perimysium associating with type V 
collagen cores. Fibril associated collagens type XII and XIV are also localized in the perimysium. 
The whole muscle is surrounded by the epimysium, which is a connective tissue layer in line 
with the tendons, indirectly attaching to the bones. Type III collagen is found in the epimysium. 
A schematic overview of the muscle structure in the different levels can be seen in Figure 1. 
 
 The intramuscular ECM is also referred to as intramuscular connective tissue (IMCT). The 
structure and organization of the IMCT can be visualized electron micrograph scans after 
digestion of the muscle fibers with NaOH. A schematic representation can be seen in figure 1. 
Collagen thickness and composition of the IMCT varies between different muscles, but 
generally type I collagen content is higher than type III. Collagens in the IMCT facilitate 
structural integrity and flexibility for mechanical force transduction, but are also implicated in 
cellular signaling.  
 
Figure 1: The architecture of skeletal muscle. Myofibrils of many actin and myosin molecules constitute 
the muscle fibers that are ensheathed in the endomysial layer. These fibers bundle together to form 
fascicles that are in turn covered by the perimysium. Fascicles are further banded and held together by 
the epimysium, connecting to the tendon and forming the muscle. 
Muscle protein turnover is a dynamic equilibrium that regulates the body composition over 
time. The basic metabolic rate is a net outcome affected by insulin and glucagon secretion 
during food intake, exercise and many other hormones such as estrogens and androgens, 
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growth hormone etc. Corticosteroids and immune mediators, such as interleukin-1 (IL-1), 
tumor necrosis factor, and interleukin-2 (IL-2) and can also have an impact on body 
composition, through modulation of appetite, food intake and direct effects on skeletal muscle 
signaling 15. 
1.1 Mechanisms of Muscle Loss  
When the dynamic equilibrium between protein synthesis and protein degradation is 
negatively skewed, muscle wasting ensues. Muscle wasting can have different onsets that vary 
in pathology characteristics and molecular pathways. At any given point, it can manifest rapidly 
(as cachexia under certain conditions as cancer or radiotherapy), moderately (in atrophy 
caused by disuse and immobilization) or progressively (because of aging in sarcopenia) (See 
Figure 2).  
 
1.1.1 Cachexia, Disuse and Sarcopenia  
Cachexia is characterized by a generalized inflammatory state leading to protein wasting and 
energy store depletion because of a disease16. Protein synthesis is defective but the major 
cause of muscle loss in cachexia is considered to be protein degradation. Many inflammatory 
mediators may play a role in muscle wasting during cachexia; IL-6 has emerged as a critical 
factor related to the maintenance of body mass during disease.  
 
Disuse atrophy is a broad definition encompassing the mechanical unloading of the muscle, 
during immobilization, bed rest or even spaceflight. Compared to cachexia, disuse atrophy does 
not normally include recruitment of inflammatory cytokines but there is noted increase in the 
production of catabolic cytokines and cortisol, based on experiments in rodents 17. During the 
initial stages of disuse related atrophy, type-I fibers are affected to a greater extend 18, 
conversely to most wasting diseases where type II fibers are generally more susceptible. Studies 
of cast-immobilization in humans have revealed that out of total decrease in leg volume, 46% 
was due to type I fiber size decrease and only 37% type II fiber decrease 19. This mass loss and 
phenotype switch is also accountable for the increased fatigue observed based on the glycolytic 
nature of fast fibers compared to the oxidative capacity of slow fibers. 
 
Sarcopenia is a syndrome that involves skeletal muscle mass and strength loss. Although mainly 
connected to aging, it can be also a result of poor nutrition, lack of exercise or poor lifestyle 
factors 20,21. Decreased levels of protein synthesis  and  degradation of controlling motor 
neurons and muscle fibers in sarcopenia,  are partly attributed to decreased levels of IGF-1 and 
induced cell apoptosis22. This is further augmented by increased levels of inflammatory 
cytokines TNF-α and TNF-β, IL-6 and IL-1 that can diminish the IGF-1 effects and accelerate 
muscle loss.  
Interestingly, there is also a noted switch of fiber type profiling in ageing muscle, where loss of 
type II fibers seems to be more favorable. In part, this can be caused after denervation of type 
II fibers, followed by reinnervation by slow motor neurons, inducing the phenotype switch. 
Fiber type degradation preference also occurs in satellite cell impairment. It is found to be more 
pronounced in type II fibers relative to satellite cells in type-I fibers, diminishing the repair 
ability in type-II fibers.  
[14] 
 
 
 
Figure 2  Overview of net and gross protein synthesis and degradation rates in muscle during various 
conditions or states. The figure clearly shows that in all but the most critically ill, net protein metabolism 
(whether it is net synthesis or net degradation) is vastly smaller than gross degradation or synthesis. 
Hence, a good biomarker or panel of biomarkers should reflect net degradation or synthesis (Figure taken 
from: Nedergaard et al, 2013) 23 
Furthermore, there is a range of neuromuscular pathologies or diseases that can cause muscle 
deterioration and compromise quality of life through impaired metabolic homeostasis and 
hindered freedom of motion. Muscular dystrophies, congenital and inflammatory myopathies 
and myositis are diverse groups of pathologies that affect more than 2 million people in Europe 
alone and are characterized by loss of muscle mass and function, frequently accompanied by 
fibrosis and/or inflammation possibly as a secondary phenomenon (further detail on 
epidemiology: http://neuromuscular.wustl.edu/).  
These diseases are mostly chronic and manifest at varying ages, from infancy to adulthood. 
Most are progressive and the severe ones are associated with significantly shortened lifespan, 
while others cause lifelong disability 24. 
 
1.1.2 Neuromuscular Disorders  
One heterogeneous group of muscle disorders is the inflammatory myopathies also called 
myositises that can cause muscle atrophy, weakness and site-specific inflammation 25. This 
group includes polymyositis (PM) and dermatomyositis (DM), two very similar manifestations 
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of that can be separated by the skin rash that patients with DM develop through calcium 
deposits in the muscle or skin. The disease can be fully or partially reversed if treated early, but 
in some cases can lead to irreversible calcification of the subcutaneous tissue and muscles, 
pulmonary fibrosis or respiratory failure and death 26.  
 
While the various forms of myositis are idiopathic, mainly inflammatory conditions, muscular 
dystrophies and congenital myopathies are genetic disorders that affect the structural integrity 
or critical signalling cascades controlling the muscle fibres 27. Dystrophies manifest a range of 
effects including, fatty tissue invasion and muscle wasting through an abnormal dynamic 
between necrosis and regeneration, thereby affecting the metabolic fitness, fibrosis and/or 
inflammation 23,28.  The most common dystrophies are Duchenne and Becker muscular 
dystrophies (DMD and BMD) Limb-Girdle Muscular Dystrophy (LGMD) and 
facioscapulohumeral muscular dystrophy (FSHD) are summarized in table 1. DMD and BMD are 
two similar pathologies that constitute the most common causes of pathological muscle loss, 
aside from sarcopenia and cachexia. Absence of a critical subsarcolemmal protein, dystrophin, 
initiates a pathophysiological cascade eventually leading to leakage, disruption and death of 
the muscle fibres, generating sustained regeneration cycles29. The exposure of intracellular 
proteins to the extracellular environment may elicit immunological reactions and thereby 
contribute to chronic inflammation. Over time, abnormal regeneration leads to progressive 
endomysial fibrosis 30–32 and displacement of muscle by fat or connective tissue 33, prompting 
fatal respiratory and cardiac implication by the third decade of the patients life.  
Likewise, LGMD is another group of heterogeneous muscle dystrophies  that are also 
characterized by degenerating myofibers, and later on infiltration of T-cells and macrophages, 
leading to a secondary inflammation 34,35.   
Lastly, FSHD is an autosomal dominant inherited neuromuscular disorder36–38 and 
predominantly affects face muscles, upper arms and the scapula. FSHD leads to premature 
disability and loss of independence despite not reducing life expectancy severely. Part of the 
disease consists of perivascular inflammation with observed fiber necrosis, phagocytosis and 
increased tissue regeneration 39.  
 
 
1.2. Common Characteristic in Muscle Wasting Pathologies  
Despite being conditions or diseases with different aetiologies, muscle-wasting mechanisms 
share several in their pathways and eventual degradation. Overlapping and non-overlapping 
traits among these conditions permit distinction between pathologies but also identification of 
mutual monitoring potential. Abnormal muscle turnover is the common denominator in all the 
pathologies, with inflammation or fibrosis playing a role in the production of potential peptide 
biomarkers 40–42 (Table 1).  
 
1.2.1. Protein Synthesis/Degradation Imbalance  
Playing a major role in hindered muscle synthesis is the increased production of myostatin as 
result of a disease or muscle disuse 43. In normal protein turnover, dietary ingestion induces 
insulin response which in turn activates the the PI3K- Akt-mTOR pathway through the insulin 
growth factor-1. (IGF-1). IGF-1 induced response triggers an anabolic response that can 
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stimulate protein synthesis and proliferation of satellite cells, while suppressing protein 
degradation at the same time. During fasting or atrophy, suppression of the PI3K- Akt-mTOR 
pathway occurs possibly via autocrine signaling inhibitors as myostatin, leading to reduced 
protein synthesis. Myostatin (growth-differentiation factor 8, GDF8) belongs to transforming 
growth factor β (TGF-β) superfamily and can inhibit satellite cell differentiation and muscle 
protein synthesis 44,45. Studies regarding 25 days of bed rest in humans resulted in 12% greater 
serum myostatin levels , which resulted in fiber atrophy and proteolysis46. 
 
Table 1: Prevalence of Myopathies and Dystrophies; histological and biochemical disease 
characteristics 
 
 
Condition 
Biochemical 
imbalance Phenotype 
Prevalence per 
100.000 References 
Muscular dystrophies 
    
Duchenne Muscular 
Dystrophy (DMD) 
Increased CK, 
MMP1, MMP2, 
MMP7, MMP9, 
fibronectin 
 Cathepsins H and 
L 
Fibrosis, inflammation, 
muscle wasting, fat 
substitution 
8 - 29  (males) 
24,47–50 
Becker Muscular 
Dystrophy (BMD) 
 
7 - 29    (males) 
Limb-Girdle Muscular 
Dystrophy (LGMD) 
Heterogeneous 
(absence of 
proteins, 
dysfunctional 
interactions etc.) 
Atrophy, endomysial 
fibrosis, inflammation in 
some cases 
0.8- 2.3  51–53 
Facioscapulohumeral 
dystrophy 
DUX4 expression in 
muscle 
Fibrosis, perivascular 
infiltration, endomysial 
inflammation  
5 36,39,54,55 
 
Inflammatory 
Myopathies 
    
     
Polymyositis (PM) 
Pro-/inflammatory 
markers increased 
Acute inflammatory 
onset (responsive to 
immunomodulation), 
muscle fiber atrophy, 
lung fibrosis 
 6.3-7.1 56–58 
Dermatomyositis 
(DM) 
6.3 
Inclusion Body 
Myositis (IBM) 
Chronic inflammation, 
muscle fiber atrophy, 
lung fibrosis (rare) 
1.5 (general 
population) 5.1 
(people >50 years 
old) 
59 
Congenital 
myopathies 
Heterogeneous Central nucleated 
fibers, Type I muscle 
fiber prevalence. rare 
inflammation 
6 (per live births) 60,61 
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In pathophysiological muscle wasting, the calcium-activated system involving the calpains, the 
ubiquitin system, and the lysosomal system involving the cathepsins, consist the main 
processes for protein degradation. A collective illustration of the processes being described 
hereon can be seen in Figure 2.  
 
Calpains (CAPN) are calcium-dependent proteases that have demonstrated a more complex 
role in muscle homeostasis. Calpains have been linked to muscle degradation through both 
apoptosis and necrosis 62 . One LGMD variation is caused due to  mutations on the CAPN3 gene 
which is exclusively expressed in skeletal muscle  53. It is believed that it also shares a  protective 
role in exercise induced stress and some calpains can inactivate upstream caspases 63.  Caspases 
are a family of proteases and their activity is related to muscle atrophy in various muscle 
wasting models involving inflammation and myonuclear apoptosis 64 
 
Muscle wasting can also occur through ubiquitination as it has been identified under atrophy 
conditions or disuse reducing muscle fibre size, increasing loss of myonuclei and proteolysis65,66. 
The muscle RING finger 1 (MuRF1), muscle atrophy F-box (MAFbx)/atrogin-1 nuclear and 
factor-kappa B (NF-κB), have been proposed to be muscle specific E3 ubiquitin ligases. 
Dysregulation of the normal conduct of intracellular signaling channels through the NF-κB 
mitogen- activated protein kinases (MAPK) pathways in skeletal muscle has been correlated to 
damage on the dystroglycan complex 67,68. Furthermore, activation of NF-κB and AP-
transcription factors 69also upregulates MMP-9 expression in a positive feedback mechanism 
observed in dystrophic muscle.  
In sarcopenia, MMP-2 and MMP-9 have a prominent role regard ECM degradation and muscle 
loss. They are very active in proteolysis of collagen IV that comprises the basement membrane 
in skeletal muscle, contribute to muscle degradation in immobilization 13,70. MMP-9 can also 
degrade collagen I, III, and V present in skeletal muscle ECM 71,72. Both MMP-2 and MMP-9 
were upregulated in a rat hind limb immobilization studies 73. MMP-2 has also shown 
intracellular activity and the ability cleave muscle specific proteins 74. 
Likewise, in mouse and dog muscular dystrophy models the dystrophic phenotype was 
associated with increases of MMP expression and when MMP expression or activity were 
inhibited, amelioration of the dystrophic phenotype was noted 75,76. Involvement of increased 
MMP levels in pathogenesis were supported by experiments held on mdx mice 77. 
 Moreover, various cathepsin mRNA isoforms were upregulated in atrophying muscle of rats 
78,79.  Cathepsin and caspase groups are known to be proteolytically active alongside with MMPs 
partaking in dystrophies and myositis.  
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Figure 3 : Schematic representation of the signaling pathways involved in a. protein synthesis and satellite 
cell proliferation after food intake and training, and b. muscle wasting through ubiquitination, apoptosis 
and autophagy. Anabolic pathways mediated through insulin-like growth factor 1 (IGF-1), can also be 
impaired in sarcopenia and cachexia caused by lower IGF-1 levels.  
 
1.2.2 Inflammation 
In many dystrophies, compromised structural integrity is a prevalent characteristic leading to 
leakage of their contents. Increased expression of major histocompatibility complex type II is 
shown in both dystrophies and myositis and a consistent T lymphocyte invasion is seen in both 
human and animal models of muscular dystrophy. Among the main inflammatory cytokines 
that have been implicated in wasting diseases are interleukin-6 (IL-6), tumour necrosis factor–
α (TNF-α), interleukin-1β (IL-1β), and interferon-γ (IFN-γ)80,81. TNF-α has been shown to 
upregulate MMP-9 in muscle cells, again through the NF-κB pathway69, augmenting ECM and 
muscle catabolism through the ubiquitin- proteasome system 101. 
In studies with transgenic mice, IL-6 overexpression resulted to skeletal muscle atrophy that 
could be diminished by administration of IL-6 receptor inhibitors 99. Aberrant expression of 
cytokines transpire the altered protein metabolism in sarcopenia. Increased levels of 
proinflammatory cytokines TNF-α and IL-6 can down-regulate GH/IGF-1 expression65  and lead 
to targeted myofibril protein catabolism69,82,83  . In cachectic cancer patients IL-6 mediates 
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skeletal muscle wasting signaling through its receptor (i.e. glycoprotein 130), which activates 
STAT3, p38, FoxO3, and atrogenes100.  
 
Collagen degradation mediated through MMP activation has been very well described in other 
inflammatory diseases. Inflammation and fibrosis are sometimes interconnected as the 
proliferation of inflammatory cells leads to overexpression of cytokines that stimulate collagen 
accretion,  i.e. TGF-β, and push native cells towards fibrogenic phenotypes (TNF, TGF-β1), 
contributing to scar tissue formation84–86. 
 
1.2.3. Fibrosis 
Fibrosis occurs after repeated degradation and synthesis cycles affecting the ECM. In 
dystrophies, development of significant intramuscular fibrosis and functional muscle tissue 
replacement has been seen consistently. Intramuscular collagen deposition leads to cardiac or 
respiratory dysfunction which are prominent contributors to mortality in dystrophy patients 87.  
Conversion of satellite cells to myofibroblasts or fibroblasts promotes accumulation of 
interstitial collagens (types 1 through 6) and proteoglycans, which in turn results in changes in 
quality and quantity of ECM88. Continuous elevation of MMP-9 hinders myofibrilar 
regeneration, promotes inflammation and fiber necrosis leading to fibrosis. Dystrophic fibrosis 
has been also  associated with higher expression of MMP-1, and -29 47 that are responsible for 
modifying the ECM. Under normal circumstances the intramuscular connective tissue is well-
ordered but in fibrosis it expands, taking the place of degraded muscle fibers with possible 
alterations in the organization of collagens (isoform ratios or crosslinking) 89. Between the 
different cytokines, TGF-β1 stands out as the main promoter of fibrosis through  augmentation 
of collagen synthesis 90. TGF-β1 can boost growth and differentiation of fibroblasts, while also 
reducing the expression of matrix degrading proteases 91.  
Collectively, the aberrant protein turnover, fibrosis and inflammation within the muscle, are 
symptoms that can be observed in many of the neuromuscular disorders. These symptoms can 
be potentially gauged through the use of different biomarkers.  
 
1.3. Biomarkers 
A biomarker is defined as a characteristic that can be objectively measured and evaluated as 
“an indicator of normal biological processes, pathogenic processes or pharmacological 
responses to therapeutic or other health care interventions” 92. Biomarkers can be qualitative 
or quantitative (e.g. histological assessment vs. bone mineral density). They can be 
investigative, diagnostic, prognostic, describe disease burden or treatment efficacy. Biomarker 
classification facilitates the selection of surrogate endpoints in a clinical study setting. Proper 
selection of endpoints is vital in clinical cohorts, to expedite and enhance the process by 
deselecting non-responding individuals earlier in the study or promote better initial selection 
of candidates, e.g. fast progressors or otherwise at-risk populations. Avoiding inclusion or 
prolonged involvement of unsuitable patients in the trials can mitigate unnecessary time and 
fund consummation, accelerating the trial process 93.  
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1.3.1 - Existing biomarkers used in myopathies 
Regarding diagnosis of many dystrophies, gene testing is available, but despite the 
identification of specific mutations verified by molecular methods 94, there is still a uncertainty 
in certain diagnoses 95,96. Muscle biopsies are often mandatory, employing 
immunohistochemical assays to identify the specificity of the pathology, the extent of 
degeneration and fatty tissue replacement. While diagnosis is somewhat adequately covered, 
assessing burden of disease and making qualified prognoses for disease trajectory is hampered 
by the severe lack of specific, robust or practical biomarkers.  
When characterizing dystrophic patients, both the current and projected quantity and quality 
of the muscle is of interest. A range of biophysical techniques as air displacement 
plethysmography (ADP), biological impedance analysis/spectroscopy (BIA/BIS), magnetic 
resonance imaging (MRI), computed tomography (CT), dual energy x-ray absorptiometry 
(DEXA) can all be used to assess muscle volume, while MRI and micro CT can even provide 
information about fibrosis 97,98. However, there are problems with availability, cost, radiation 
exposure, accuracy, discrepancies between clinicians or machines that limit the use of all of 
these tools in routine clinical practice 99–103. Imaging techniques (DXA, MRI and CT) are rarely 
used in monitoring of muscle diseases as the information they provide is considered of limited 
clinical utility, compared to the expense and possible radiation exposure associated with their 
use. 
Stable isotope based techniques have been employed in an attempt to measure protein 
metabolism. Besides also requiring repeated muscle biopsies, the validity of measuring of 3-
methylhistidine in serum or urine as a muscle protein degradation marker has been questioned. 
As 3-methylhistidine can originate from non-skeletal muscle tissue, total levels in serum and 
release kinetics can interfere with obtaining the true values 104. 
Muscle function or quality is usually assessed through functional testing. Isometric grip 
strength, sitting and rising from a chair or six minutes walking tests are common examples of 
the functional tests used in clinical studies and settings 105. However, strength and endurance 
tests (sitting/rising, walking test) suffers from high variability and risk of intra-rater differences. 
Most dystrophies and myopathies cause muscle weakness, increased incidence of muscle fiber 
degeneration and regeneration and increase levels of Creatine Kinase (CK) levels in serum. 
Although CK and myoglobin (Mb) in serum are used as indicators of general muscle injury or 
degradation, neither are capable of indicating the source or the extent.  
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Table 2: Summary of current biomarker classes regarding monitoring changes in skeletal muscle 
ADP: Air Displacement Plethysmography, BIA/BIS Biological Impedance Analysis/Spectroscopy, MRI: Magnetic 
Resonance Imaging CT: Computed Tomography, DXA: Dual X-ray Absorptiometry, CK: Creatine Kinase, Mb: 
Myoglobin, PIIINP: Pro-Collagen III, MMP-9: Matrix metalloproteinase-9 
 
Creatine Kinase is so far the main biomarker for assessing disease activity (“burden of disease”) 
and is a marker of sarcolemma disruption and membrane leakage that is routinely used in the 
past decades. Despite being obligatory for diagnosis of some dystrophies as BMD 106 values of 
CK in serum strongly vary between and within patients. Generally there is a strong increase of 
CK up to 200-fold in DMD/BMD patients, but the levels lower with age, fibrosis progression and 
the extensive loss of muscle mass  that takes place107 108. Therefore, CK cannot provide viable 
information on the extent of the damage and biopsies cannot be repeated over time to 
facilitate sufficient monitoring over the course of a treatment.  
More importantly, little or no robust protein based biomarkers are available for prognosis of 
the disease or early indicators of response to a treatment. Therefore, there is a lack of 
biochemical markers that can predict or monitor tissue turnover. It is of significant interest to 
find biomarkers reflecting protein metabolism, which will be more sensitive in monitoring 
tissue loss than current techniques.  
In clinical trials, easily obtainable biomarkers that can detect treatment response at an early 
stage can assist in selecting better-suited candidates for cohorts or exclude patients that show 
no progression. Serum biomarkers have demonstrate such abilities in clinical studies as 
potential candidates for prognosis, stratification or response to treatment 109–113. Considering 
the size of the muscle mass, the quantitative and qualitative changes in protein turnover 
associated with these pathologies and the degree of leakiness in healthy and diseased muscle 
Biomarker class Examples Advantages Disadvantages Refs 
 
Biophysical 
 
ADP,  BIA/BIS, MRI, CT 
DXA 
 
 
Generally good sensitivity and 
on par specificity with other 
methods 
 
Problems with availability on site, 
cost, required expertise and 
exposure to radiation, rarely used 
for longitudinal studies 
97–103 
 
 
 
 
Functional test Isometric grip strength Easy to implement in most 
studies, reflecting quality of life 
Affected by many variables that 
cannot be controlled, intra- and 
inter- test variation 
105 
 6 minute walking  
 Sit and rise  
   
Biopsy based  Immunohistochemistry Very good and robust methods, 
high sensitivity 
Require muscle biopsy which is not 
sustainable method over time, 
biopsy site bias, possible specificity 
problems 
104 
 stable isotope 
 
 3-methylhistidine 
 
  
 
 
Serum  CK, Mb, MMP-9 
Collagen markers 
Easily obtained through routine 
blood sampling, applicable in 
sensitive ELISA assays, low 
volume needed, less invasive, 
cost effective in large studies 
Specificity problems with the 
biomarkers routinely applied (CK, 
Mb), other biomarkers although 
promising, have not been fully 
validated in large cohorts 
 
 106 
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fibres, muscle pathologies can result in release of pathology-specific peptides that can be used 
as serological or urinary biomarkers 114,115.  
Many bioinformatic approaches as protein sequencing, MS/MS and large-scale screening have 
been followed in order to identify possible protein candidates that can potentially serve as 
biomarkers for sarcopenia, cachexia or muscle dystrophy.  
A comparatory MS analysis between 5 DMD patients and 5 healthy controls revealed that many 
N- or C- terminal sequences of titin could be observed and confirmed by western blot analysis 
116. However, the biomarker did not demonstrate strong specificity and was not validated in a 
larger cohort regarding the efficacy as a non-invasive monitoring method in dystrophies. 
However, a cohort of this sort would still be bound to the vast differences in an age-matched 
control group. As DMD is affecting children, the healthy subjects would be in a constant 
growing stage in different rates. Growth naturally affects the turnover of many of the proteins 
of interest in children of that age, inducing difficulties in a comparative study.  
Proteases as MMP-9 have also been proposed as a specific biomarker of monitoring DMD 
progression as it has been found to be significantly upregulated compared to healthy subjects. 
In a study involving ambulant and non/ambulant males suffering from DMD differences in 
serum MMP-9 levels were observed compared to a control group of healthy boys117. It has to 
be noted that the natural MMP-9 inhibitors were also upregulated in the patient group, making 
the effect of MMP-9 values alone hard to interpret. Lastly, levels of  fibronectin in serum have 
been studied as a method of determining fibrosis based on a polyclonal antibody competitive 
ELISA 50. Although demonstrating mixed diagnostic potential it did not have success in the 
longitudinal part of the study.  
 
1.3.2 Neoepitope biomarkers 
One possible type of biomarkers showing promise regarding specificity are neoepitope peptide 
biomarkers. These are biomarkers in which pathology-specific post-translational modifications 
on distinct proteins, generate disease-specific epitopes. Any peptides whose production in vivo 
is pathology-related may therefore be used as biomarkers. For instance, in some 
dystroglycanopathies there is an aberrant glycosylation of α-dystroglycan that has served as an 
epitope for immunohistological examination of biopsies118. Unfortunately, this abnormality is 
observed in a small subset of dystrophic patients and although it is an interesting target, the 
neoepitope might not be available in blood circulation. A good neo-epitope biomarker needs 
to be applicable in as many patients in a specific disease as possible and readily available in 
bodily fluids. In this respect, neoepitope peptides produced through pathology-specific 
proteolytic cleavage are particularly interesting, because proteolytic activity is well known to 
be modulated in a large number of pathologies119–121. As the sarcolemma becomes permeable, 
smaller peptides produced upon proteolysis can leak into the circulation more easily than do 
intact proteins, making them measurable in serum and plasma or even urine 122. 
In drug development, neo-epitope biomarkers can improve the clinical trial process by other 
generating early data in pre-clinical drug tests or facilitating completion of endpoints in terms 
of efficacy or response to treatment. Indeed, the most common reason for in clinical 
development is lack of proof of efficacy or unacceptable toxicity. Biomarkers can be used in 
preclinical studies to early address potential toxicity issues or help select the most promising 
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compounds123. Neoepitope biomarkers have been successful in advanced clinical trials, 
demonstrating a timely response to treatment 124,125.  
1.3.3 Existing neo-epitope biomarkers 
A stellar example of a highly specific neoepitope biomarker is the cathepsin K cleaved carboxyl-
terminal collagen cross-linked biomarker of collagen type I (CTX-I) that has become the gold 
standard of bone turnover 126,127. This is a result of the near exclusivity of osteoclasts expressing 
the protease in combination with the high abundance of type I collagen in bone. Thusly, any 
fragment detected in circulations is tightly associated with total osteoclast activity, hence 
related to the process of bone loss/turnover. Such a strong and specific correlation allows for 
early detection of bone loss, compared to conventional methods of quantification e.g. DEXA 
scanning. CTX-I has been quite successful at prognosing response to therapy interventions 
regarding the bone turnover within a quite short time frame 128.  
Similarly, MMPs or ADAMTS (A-Disintegrin And Metalloproteinase) can function as disease 
specific proteases that can interact with relevant tissues as the already discussed collagen rich 
ECM to monitor aberrant turnover 129. A range of proteolytic peptides derived from collagens 
1 to 6 produced by MMPs, calpains or caspases has worked as biomarkers of many ECM-related 
diseases as ankylosing spondylitis 130 , OA 131 , RA 132, kidney fibrosis 133, lung fibrosis and liver 
fibrosis 134. Also, some of these collagen peptide biomarkers as well as proteolytic fragments of 
C-reactive protein (CRP), namely MMP-cleaved CRP (CRPM), have shown to be biomarkers of 
the tissue inflammation135. Because of the shared molecular origins of these markers and the 
proteases involved in the previously described muscle pathologies there is a high likelihood 
that several of these biomarker can find use in neuromuscular disorders (Table 2).  
In skeletal muscle, currently, the N-terminal pro-peptide of type III collagen (Pro-C3) is a 
promising biomarker since it has shown to correlate with the anabolic response to hormone 
treatment 136. Understanding the muscle protein-turnover systems will help us identify 
potential biomarkers. Several proteolytic systems are involved in the muscle protein turnover, 
most notably the calcium dependent pathways (caspases and calpains), the lysosomal 
pathways and ubiquitin-proteasome system pathways 137–139.  The specific muscle turnover 
products generated by proteolytic systems would change along with the altered protein 
metabolism and possibly reflect the muscle loss process. 
 
With reference to the muscle ECM in clinical immobilization studies, changes of MMP-
generated collagen VI levels were found to be associated with muscle regrowth following 
immobilization 140. In skeletal muscle, Pro-C3 has also been demonstrated to be a potential 
biomarker reflects the anabolic response to therapy in old people 142.  
In the case of skeletal muscle extracellular matrix, there is a complex distribution of the 
different collagens in the various layers of the ECM and the connective tissue, while the effect 
depends on the nature of the specific disease 144. As mentioned before, fibrosis is by definition 
the consequence of abnormal ECM turnover, resulting in excessive deposition of ECM proteins, 
especially collagens I, III and VI 143. Fragments of these constituents or their corresponding 
propeptides detected in circulation have been shown to reflect the extent of fibrosis and ECM 
remodeling in rats 145 and even demonstrate response to antifibrotic treatment 146,147. Indeed, 
Pro-C3 has been proposed in assessing collagen III formation in fibrosis models 141 (Table 3). 
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This has also been demonstrated as the case for myopathies and dystrophies, where endo- and 
perimysial fibrosis in the form of accumulated collagen I, III, IV and fibronectin predominates 
148,149. In DMD, endomysial fibrosis has been one of the strongest predictors of motor 
deterioration. Myostatin inhibitors and several putative antifibrotic treatment routes are being 
looked into. Previous preclinical and in vitro studies have documented that myostatin inhibitors 
downregulates markers of fibrosis, but this has not been shown conclusively in clinical models 
yet 150,151. 
 
Table 3: Neoepitope biomarkers with relevance to neuromuscular disorders covering a spectrum of 
processes connected to the disease 
Type of 
marker 
Related to process Application in muscle Refs 
C1M, C3M Collagen 1,3 
degradation 
Inflammation in muscle 
tissue 
152 
PINP, C1M Collagen I synthesis, 
ECM remodeling  
Fibrosis 145,153 
CAF Agrin fragmentation Functional disintegration in 
neuromuscular junction, 
sarcopenia 
154 
Titin Muscle metabolism Muscle turnover 116,155 
 
An interesting neo-epitope describing fragmentation of the C-terminus of agrin by neurotrypsin 
in the neuromuscular junction has been recently presented 154. The 22kD C-terminal agrin 
fragment correlates with neurogenic sarcopenia. This marker aims at assessing the underlying 
condition at the neuromuscular junction, which correlates with the decline of muscle mass in 
males. 
Similarly, muscle atrophy is also associated with proteolytic cleavage of internal proteins and 
progressive tissue loss. An MMP-2 generated titin fragment biomarker has been previously 
developed and applied in disuse cohorts 155. Even though titin is a very big protein, metabolic 
byproducts from intracellular protein degradation could enter the circulation, exhibiting a very 
early response of disuse atrophy.  Compared to the terminal biomarkers discussed before, this 
neo-epitope biomarker holds the specificity advantage as it will only be available upon 
interaction of the substrate and the protease. Generated peptides can be possibly used as 
biomarkers of the myofibrillar proteins turnover in the muscle and thus provide information 
about ongoing muscle catabolism or anabolism. Indeed, serum Troponin I has been shown to 
be increased in dystrophic patients 156. These intracellular proteins, particularly from the 
myofibrillar fraction as they display the greatest degree of tissue specificity, show promise as 
biomarkers of muscle turnover. 
 
The focus of this thesis is to develop an assay based on a good muscle specific protein candidate 
and assess the assay validity in relevant muscle wasting models. Furthermore based on the 
information provided in the previous chapters, already existing collagen based biomarkers 
were of interest regarding their application in muscle pathologies.  
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2.  RESEARCH PURPOSE, HYPOTHESES AND AIMS 
 
As established in the background section, there is a need for well-characterized biomarkers 
that can serve to observe changes in muscle and reflect parts of the pathology of diseases. In 
paper I, the specific needs for monitoring muscle wasting, inflammation and fibrosis in drugs 
that are currently in advanced clinical trials are described. Existing biomarkers to describe 
progression or improvement in these pathologies at an early state have yet to be found. 
Research groups have taken different approaches addressing this need, varying from repeated 
anthropometric measurements to immunohistology in biopsies and recently micro RNA 
biomarkers.   
Protein biomarkers in serum are easily obtainable, not as invasive as other methods and can 
be used as targets for antibody-based assays. In our disposal, we had a panel of already 
validated protein biomarkers, mainly targeting the collagens in the ECM, which have 
demonstrated potential in describing this processes in other diseases. We wanted to test if 
those protein fingerprint biomarkers could be released through inflammatory mechanisms of 
myopathy patients. If so, a second question would whether these biomarkers can characterize 
and distinguish between healthy individuals and patients with different myopathy diseases 
(manuscript II). In that study, biochemical tests describing the inflammatory component as well 
strength and functional tests were available. Using those tests, we could test the ability of 
biomarkers to correlate with the outcomes of those tests. Furthermore, we wanted to examine 
the possibility of developing novel biomarkers to address the degradation and release 
processes of muscle specific proteins in wasting models or therapeutic interventions 
(manuscript III).  
 
The overall hypothesis is that both the ECM and myofibrillar biomarkers are released in 
circulation of people with muscle pathologies and can describe the underlying mechanisms of 
the muscle conditions, as well as the putative response to an intervention. The premise of the 
individual hypotheses is described below, separately for each study. 
 
2.1 Idiopathic Inflammatory Myopathies (Study I) 
In myositis, inflammation is part of the cause of the pathology, in contrast to congenital 
dystrophies, where it is a secondary phenomenon. Inflammation contributes to the symptoms 
and declined functionality, making it a relevant pathological mechanism to treat. 
Glucocorticoids have been shown to slow loss of locomotor function or even provide temporary 
improvements and are recommended as first-line treatment in both myositis 157–160 Biological 
anti-inflammatory drugs like inhibitors of TNF-alpha, IL-2, IL-6 or type I interferon have already 
shown promise in this regard in both inflammatory myopathies 161–164. 
Activation of inflammatory pathways and increased proteolytic rates in myositis have been 
shown to be associated with overexpression of MMPs, localized in the muscle fibers 165. Thus, 
proteolytic fragments generated by MMPs appear to be good biomarker candidates. Assays 
directed at monitoring changes in the aforementioned pathologic manifestations have been 
successful in providing information for developing therapies for similar diseases during clinical 
trials. In study I, there was a group of dermatomyositis patients, a group of polymyositis 
patients and a control group. In addition to serum samples obtained from all the participants, 
trained physicians performed muscle strength assessment.  
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Individual aims for this study were: 
Aim 1a: Test if inflammatory biomarkers and ECM based neo-epitopes can be used to 
distinguish diseased populations from control group or populations with different diseases 
Aim 1b: Determine whether ECM based biomarkers can reflect functionality or force 
generation capacity of affected muscle groups. 
 
2.2 Cachexia, Disuse Atrophy and Training (Studies II and III) 
As loss of muscle tissue and associated muscle function is a trait of most myopathies, 
therapeutic approaches aimed at restoring functional muscle mass are under examination. 
There is a long record of cancer patients undergoing rapid muscle loss with or without any 
chemotherapy or radiation treatment. Patients are submitted to rehabilitation programs 
including resistance or other training sometimes together with dietary changes and 
pharmaceutical supplementation. Training has been also proposed as both a counter measure 
during long periods of bed rest or as a method of restoring loss of muscle back to normal levels. 
As discussed previously, myofibrillar proteins and protein fragments, such as the previously 
described MMP-cleaved Titin fragment, can enter the circulation and may show promise as 
biomarkers of muscle protein turnover and by extension, catabolism or anabolism. However, 
these peptide biomarkers have yet to show promise in terms of being biomarkers of anabolism, 
or catabolism and by extension anabolic treatment response. 
In study II, a group of cancer patients after radiotherapy was admitted to a resistance-training 
program alongside to a control group that followed the same training regime. Serum samples 
were obtained right after radiotherapy, before and during the training period.  
In study III, healthy subjects were put in 56 days of bed rest, split in a group with resistance 
vibration exercise as a countermeasure and a group with no countermeasure at all. After the 
bed rest period, both groups entered the same rehabilitation process for a period of 128 days. 
Throughout the entire study, frequent blood samples were collected.  
We developed an assay directed at the C-terminal of troponin T1 (TNNT1) that was measured 
in both of the mentioned studies. 
 
The specific aims were: 
Aim 2a: Demonstrate that the TNNT1 biomarker can be released and detected in blood 
circulation under muscle damage in a distinct manner compared to normal physiology. 
Aim 2b:  TNNT1 can follow the catabolic/anabolic effects induced by the disuse model and the 
training intervention in both studies.  
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3. BIOMARKER POTENTIAL IN DRUG DISCOVERY FOR 
NEUROMUSCULAR DISEASES 
 
Manuscript I 
Neo-epitope peptides as biomarkers of disease progression for muscular 
dystrophies and other myopathies  
 
Aim 
This review paper covers the specific needs for monitoring muscle wasting, inflammation and 
fibrosis in neuromuscular diseases. Possible methods of using biomarkers for monitoring 
those processes are discussed. Clinical trials in advanced stage at the time are mentioned and 
methods to benefit from serum biomarkers are proposed.  
 
Conclusions 
Neoepitope peptide biomarkers hold great potential in this respect, as they have been 
successful in characterizing localized pathological protein turnover, fibrosis and inflammation 
in a range of other diseases.  
Current treatments are mainly targeted on dealing with the inflammation or fibrosis either 
directly (anti-inflammatory, anti-fibrotic) or indirectly (exon skipping). By using neoepitope 
biomarkers, improved characterization of these traits could strengthen or speed up ongoing 
clinical trial efforts as they can contribute to disease progression monitoring, treatment 
efficacy and stratification/selection for participating patients.  
 
Note 
Parts of this review paper were discussed in the introduction part of this thesis. 
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4. PROTEIN FINGERPRINT BIOMARKERS OF THE 
EXTRACELLULAR MATRIX  
 
Manuscript II 
Collagen turnover biomarkers assist in differential diagnosis of different 
forms of myositis 
Aim 
Inflammatory myopathies, or myositis, cause pain and loss of musculoskeletal mass and 
function. Inflammation is associated with dysregulation of extracellular matrix (ECM) giving 
rise to neo-epitope peptide biomarkers that have shown promise as diagnostic or prognostic 
tools in several other inflammatory and degenerative conditions. The purpose of the current 
study was in a prospective manner to elucidate to what extent ECM turnover markers 
correlated with diagnosis and physical function in patients with dermatomyositis (DM) and 
polymyositis 
Introduction to the cohort 
In a cohort of 51 myositis patients (28 DM, 23 PM), we measured a range of neo-epitope 
biomarkers derived from cleavage of collagens I (C1M and PINP), III (C3M and PRO-C3), VI 
(C6M) and C-reactive protein (CRPM). We then related these to PM and DM diagnosis. 
Secondly, we performed Spearman’s correlation analyses of the Interferon gene score in both 
muscle and blood, as well as Manual muscle testing (MMT8) score to the assessed 
biomarkers. 
 
Main findings 
The levels of the biomarkers CRPM and PINP were downregulated in DM and PM patients 
relative to healthy controls, whereas PRO-C3 was found to be increased in DM. In DM only, we 
found that C1M and C3M were upregulated relative to controls. 
Secondly, biomarker panels correlated with Interferon gene scores in blood for PM and DM; 
however, the correlations were seen for different markers in the two diagnostic groups. Thirdly, 
we found that CRPM correlated well with the MMT8 score for DM.   
 
Conclusions 
Both DM and PM significantly affect several of the biomarkers measured in this study, most 
prominently CRPM and PINP, indicative of significantly altered turnover of extracellular matrix 
components and CRPM.  C3M correlated with Interferon gene score, in PM and DM, and 
CRPM with MMT8 score in DM. The biomarker panels could be of use in myositis diagnosis, 
functional patient characterization and monitoring of treatment efficacy.  
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Collagen turnover biomarkers assist in differential 
diagnosis of different forms of myositis 
 
Athanasios Arvanitidis1  , Xiang Guo2, 1, Brandon W. Higgs2, Christopher Morehouse2, Philip Z. 
Brohawn2, Morten A. Karsdal1, Kim Henriksen1, Wendy I White2 
 
 
Abstract 
 
Background 
Inflammatory myopathies, or myositises, are serious inflammatory conditions affecting muscle, causing 
pain and loss of musculoskeletal mass and function. Inflammation is associated with dysregulation of 
extracellular matrix (ECM) turnover giving rise to neo-epitope peptide biomarkers that have shown 
promise as diagnostic or prognostic tools in several other inflammatory and degenerative conditions. 
Thus, the purpose of the current study was to elucidate to what extent ECM turnover markers correlated 
with diagnosis and physical function in patients with dermatomyositis (DM) and polymyositis (PM).  
Materials and Methods 
In a cohort of 51 myositis patients (28 DM, 23 PM), we measured a range of neo-epitope biomarkers 
derived from cleavage of collagens I (C1M and PINP) and III (C3M and PRO-C3), C-reactive protein-M 
(CRPM) and C6M. We then related these to PM and DM diagnosis, as well as levels in matched healthy 
controls. Secondly, we performed Spearman’s correlation analyses of the Interferon gene score in both 
muscle and blood, as well as Manual muscle testing (MMT8) score to the assessed biomarkers.  
Results 
We found that the levels of the biomarkers CRPM and PINP were reduced in DM and PM patients relative 
to healthy controls, whereas PRO-C3 was found to be increased in DM. In DM only, we found that C1M 
and C3M were increased relative to controls. 
Secondly, we found that C3M levels correlated with Interferon gene scores in blood for PM and DM; 
however, the correlations were seen for different markers in the two diagnostic groups. Thirdly, we 
found that CRPM correlated well with the MMT8 score for DM.   
Discussion/Conclusion 
We have found that both DM and PM significantly affects several of the biomarkers measured in this 
study, most prominently CRPM and PINP, indicative of significantly altered turnover of extracellular 
matrix components and CRPM. Furthermore, we found that C3M correlated with Interferon gene score, 
in PM and DM, and CRPM with MMT8 score in DM. Thus, a combination of neo-epitope biomarkers could 
be of use in myositis diagnosis, functional patient characterization and monitoring of treatment efficacy. 
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Background 
 
Myositises are for the major part comprised by the idiopathic inflammatory myopathies: polymyositis (PM), 
dermatomyositis (DM) and inclusion body myositis (IBM). The prevalence of inflammatory myopathies have 
been reported ranging from 10 to 100 per million, making them a fairly rare group of diseases. Their prevalence 
increases with age and is higher in women than in men as is the case with most inflammatory conditions[1,2]. 
Diagnosis is normally made through the presence of muscle weakness, elevated Creatine Kinase (CK), 
abnormal EMG finding and abnormal histological findings in tissue samples. If there are dermatological 
symptoms, then the diagnosis is usually DM. From a clinical perspective, PM and DM are often grouped 
together as they share several pathological traits and both respond to anti-inflammatory treatment. While 
IBM may appear similar to PM, it is unresponsive to normal anti-inflammatory treatment, making the 
unresponsiveness to steroid treatment one of the main factors separating it from PM. For all the myositis 
manifestations, autoimmunity plays an important part in the pathology [1,2].  
Treatments of myositises are symptomatic and when considering anti-inflammatory biologicals, treatment 
choices of myositisis are limited and new drug development is needed. However, biomarkers of disease activity 
are not well developed and easily assayed biomarkers monitoring disease aspects, such as inflammation, 
muscle integrity and response to treatment, would benefit both patients and clinical development. 
Chronic inflammation in all tissues is associated with dysregulation of turnover of extracellular matrix 
components, most prominently in the form of upregulation of expression and activity of proteases and 
sometimes parallel increases in expression of extracellular matrix constituents. The increase in proteolytic 
activity gives rise to peptide fragments that can be measured in serum. This has been shown particularly with 
MMP-cleaved fragments of collagens I, II, III, IV and VI in a range of pathologies, where local upregulation of 
MMPs is playing a part in the pathology [3–9]. 
In a similar way, during synthesis of the fibrillar type I and III collagens, propeptides are secreted as part of the 
maturation of the protein and can thus be used as a surrogate measure of synthesis of these proteins, thereby 
providing us with surrogate measures of both synthesis and degradation of extracellular matrix constituents 
[9–12]. 
In both PM and DM, increased expression and activity of Matrix Metallo-Proteinase (MMP) enzymes from the 
gelatinase (MMP-2 and MMP-9) and collagenase (MMP-1) families have been reported in muscle [13]. 
As 30-40 % of the body mass consists of muscle and collagens I, III, IV and VI are highly abundant in the epi,- 
peri- and endomysial fascia layers surrounding muscle fibres [14] [15]. The combined abundance of these 
collagens and increased activity of especially MMP-enzymes in muscle makes turnover markers of these 
proteins possible biomarkers of myositis conditions.  
Lastly we decided to include a metabolite of C-reactive protein (CRP), in the screening panel. CRP has been 
shown to be upregulated in some myositis cases, particularly DM [16].  The CRPM peptide fragment produced 
from MMP-cleaved CRP has previously been shown to be associated with localized inflammation in both osteo- 
and rheumatoid arthritis, indicating that it is a locally produce metabolite of CRP[5,17,18]. Given the 
inflammatory nature of myositis, and the previously discussed involvement of MMP proteases, we decided to 
examine whether also this biomarker could be indicative of pathology in DM or PM myositis. 
[45] 
 
Thus, the purpose of the current study was,  to elucidate if the biomarkers C1M, C3M, C6M, PINP, PRO-C3, 
and CRPM either by themselves or in combination would be related to myositis diagnosis, or functional status 
in the form of IFN gene score and  MMT8 score in a cohort of PM and DM subjects. 
 
Materials and Methods 
Subjects 
51 myositis patients (23 with PM, and 28 with DM, diagnosed according to the Bohan and Peter criteria) and 
30 healthy age- and gender matched controls were included in a clinical trial described previously 
(NCT00533091) [19,20]. Subjects had blood drawn, clinical characterization including manual muscle testing 
(MMT8) and muscle biopsy specimens taken. The results and data points used in this paper are derived 
exclusively from the baseline measurements, and the demographics have previously be published [19,20]. 
Interferon gene signature  
The IFNGS score was calculated using 13 type I IFN-inducible genes (IFI27, RSAD2, IFI44L, IFI44, OAS1, IFIT1, 
ISG15, OAS3, HERC5, MX1, ESPTI1, IFIT3, and IFI6) and reported as a median fold change relative to a pool of 
normal control samples, as described previously [21]. The effects on IFN score in this trial have been reported 
before [19–21]. 
Muscle testing 
Muscle testing was done by manual assessment of strength in a subset of 8 muscles, i.e. neck flexors, deltoids, 
biceps, wrist extensors, gluteus maximus and medius, quadriceps and ankle dorsiflexors, as previously 
specified in the MMT8 muscle inventory [22].  
 
Neoepitope biomarkers 
Biomarker measurements of serum peptide biomarkers C1M, C3M, C6M, P1NP, PRO-C3, and CRPM were 
performed in serum samples as described previously[3,8,23–26]. All biomarkers were measured in duplicates 
and when the CV in a duplicate measurement was above 15%, the sample was re-measured. 
 
Statistics 
When we tested for differences in biomarker levels between healthy subjects, DM and PM patients, we did a 
one-way ANOVA across groups with post hoc testing using Tukey’s correction for multiple testing (done in 
Prism 6 for Mac OS X). 
To assess correlations between IFN scores, MMT8 and the biomarkers, Spearman’s ranked correlation analysis 
was performed with no adjustment for multiple comparisons.  
[46] 
 
Results 
 
Biomarkers in relation to diagnosis 
The baseline demography has been published previously, and showed that the cohort was 
balanced from and age and gender point-of-view [21]. 
For the type I collagen synthesis biomarker PINP, a statistically significant lowering was 
observed in dermatomyositis and polymyositis, and there appeared to be no difference in the 
levels between the two groups (Figure 1A). For the biomarker of MMP-mediated degradation 
of type I collagen, we observed a different pattern, with the DM group being significantly higher 
than the healthy group as well as the PM group, which was not different from the controls.  
For synthesis of type 3 collagen, we measured Pro-C3, and as seen in figure 1C, Pro-C3 levels 
were elevated in the DM group, when compared to the healthy controls. In the PM group the 
Pro-C3 levels appeared to be somewhat elevated compared to the controls, but this did not 
reach statistical significance. For the type 3 collagen degradation marker C3M, the pattern was 
very similar, with significantly high levels in the DM group compared to healthy controls, and a 
trend towards an increase in the PM group compared to controls.  
For CRPM (CRP degraded by MMPs), we found that the levels were significantly lower in the 
two myositis groups than in the healthy controls. Finally, for type 6 collagen degradation (C6M), 
we observed no differences between the groups.  
 
Biomarkers in relation to IFN signatures and MMT8 score. 
To assess the relationship between the collagen turnover biomarkers and the IFN signature in 
the blood and muscle, we assessed Spearman’s ranked correlations between the biomarkers 
and the two IFN signatures as well as MMT8 scores at baseline (Table 1).  
For DM we found a significant positive correlation between the IFN gene signature assessed in 
blood and C3M, as well as a significant positive correlation between MMT8 and CRPM levels. 
In DM, no other significant correlations were observed.  
In PM, significant positive correlations between CRPM levels and IFN blood, as well as C6M 
levels and IFN in blood were noted, while no other significant correlations were observed. 
No correlations between biomarkers and IFN scores in muscle were observed, despite a 
significant correlation between the two IFN scores (Spearman’s r of 0.7, p<0.001). 
 
Table 1: Spearman’s r correlation coefficients for the biomarkers, the IFN scores and the 
muscle output.  
 C1M PINP C3M  Pro-C3 CRPM C6M 
DM IFN Blood 0,002 0,33 0,40* -0,02 0,32 -0,18 
IFN Muscle -0,18 0,10 0,14 0,15 -0,03 -0,27 
MMT8 -0,01 -0,17 0,38 -0,03 0,46* 0,21 
PM IFN Blood 0,24 0,11 0,40 0,25 0,45* 0,42* 
IFN Muscle 0,05 0,04 0,16 0,22 0,12 0,13 
MMT8 -0,20 0,01 -0,36 -0,34 -0,37 -0,38 
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 Figure 1: Biomarker levels in the three diagnostic groups.  
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Discussion 
Biomarkers across PM and DM. 
We here present data indicating that differential diagnosis of PM and DM can be possibly 
facilitated  using collagen turnover biomarkers. Furthermore, in this small study we were able 
to identify relationships between the biomarkers and both inflammatory indicators, such as IFN 
score in blood, as well and the functional score MMT8. Data which clearly indicate that the 
collagen turnover biomarkers are of relevance when developing therapies for the different 
forms of myositis.  
We found that either type of myositis was associated with substantial decreases in CRPM and 
PINP biomarkers relative to controls, whereas DM alone was associated with increases in PRO-
C3, C1M and C3M.  
CRPM has previously been described as a biomarker of local inflammation, which was elevated 
in conditions, such as rheumatoid arthritis and in subgroups of osteoarthritis patients [17,18]. 
We were intrigued to find that CRPM was strongly reduced in both DM and PM, relative to 
healthy subjects. This contrasts with the previous findings, as myositis is characterized by 
increased inflammatory status as well as increased MMP activity. One possible explanation 
could be a difference in MMPs involved in myositis and arthritis, and hence a different 
processing of CRP locally in the tissues. Alternatively, it could relate to the progression status 
of the disease; however, this remains to be elucidated.  
Our reported reduction of PINP matches with a previous myositis study where PINP was found 
to be reduced, while PICP, the carboxyterminal fragment of collagen type I was upregulated 
[27]. 
In the literature, both of these biomarkers are associated with synthesis and maturation of 
collagen I, so these findings might be reflecting more on the disease activity which leads to the 
abnormal turnover of type I collagen. In fact, immunohistochemical studies in polymyositis 
patients have shown increases in the amount of collagenous tissue, e.g. fibrosis [28]. This could 
possibly be a basis for our findings, as fibrosis is associated with not just increased amounts of 
collagenous tissue, but also qualitative changes in turnover [3] [8]. 
For PINP, the observed downregulation in both types of myositis was similarly hard to 
understand. Our reported downregulation of PINP matches with a previous myositis study 
where PINP was found to be downregulated, while PICP, the carboxyterminal fragment of 
collagen type I was upregulated[27]. In the literature, both of these biomarkers are associated 
with synthesis and maturation of collagen I, so these incongruent findings must reflect specific 
turnover anomalies in myositis that have not yet been characterized. Thus, normally we would 
interpret a decrease in PINP as a marker of reduction in collagen I synthesis, but given the 
findings from the Kubo study, this warrants more consideration. Immunohistochemical studies 
in polymyositis patients have shown increases in the amount of collagenous tissue, e.g. 
fibrosis[28]. This does not necessarily contradict our findings, as fibrosis is associated with not 
just increased amounts of collagenous tissue, but also qualitative changes in turnover [3,8]. 
[49] 
 
For the collagen type 3 turnover biomarkers (C3M, ProC3), we found increased levels in the 
DM group, indicating that type 3 collagen turnover is upregulated in DM. Furthermore, a trend 
towards increased levels was observed in the PM group. Interestingly, a case-study conducted 
using another assay measuring the total pro-peptide of collagen type 3 (not exclusively the 
matured collagen III as Pro-C3) also found elevated levels in myositis compared to control 
values, supporting the findings presented here [29].  
Neither C1M nor C6M has been measured previously in myositis. As for C1M we think that the 
increase of C1M and C3M in DM, but not in PM, could possibly be explained by the involvement 
of skin in DM. This would imply that the C1M and C3M peptides found in DM but not in PM are 
actually produced in the skin; however, this will obviously need to be confirmed in other 
studies. As for C6M, no significant changes manifested between groups and none were 
expected.  
While these data are obviously generated in a cohort of somewhat limited size, it is very 
encouraging that the collagen turnover markers, especially the collagen type I and collagen 
type 3 markers, are able to aid the separation of DM from PM, something that has not been 
before. This indicates that implementation of these biomarkers in which could potentially help 
in development optimized treatments for the various forms of myositis in the future.  
 
Neoepitope biomarkers vs. IFN gene signature 
A range of biomarkers, wet and dry, have been proposed in relation to myositis. As the IIMs are 
inflammatory by definition and PM and DM are responsive to anti-inflammatory treatments, 
one of the wet biomarkers that have been used extensively in recent years is the interferon 
gene signature. This has been shown to correlate (R2 of 0.3-0.4) with global and muscle-specific 
soreness as well as several other myositis biomarkers[30,31].  
This formed the basis for our desire to compare the neoepitope biomarker panels with 
Interferon gene signatures in both blood and muscle.  
Interestingly, the biomarker C3M showed a significant correlation (Spearman’s r=0.4, p<0.05) 
with IFN score in blood in DM, and a borderline significant correlation in PM (Spearman’s r=0.4, 
p=0.056), indicating that C3M which is considered to be a marker of systemic inflammation is 
related to the IFN score in blood. Interestingly, in the PM group CRPM and C6M were also 
correlated to the IFN score in blood, while this was not observed for DM. In fact, if anything the 
C6M marker, albeit not reaching statistical significance, was inversely correlated to IFN score 
in blood in DM, again supporting that the neo-epitope biomarkers provide differential output 
in the two myositis groups.  
For the IFN score in muscle, we observed no correlations to any of the serum biomarkers.  
 
Neoepitope biomarkers correlate with MMT8 score 
[50] 
 
Next, we wanted to find out if the biomarkers we measured had any relationship with the 
functional status of the subjects in the form of the MMT8 measurement obtained in this study.  
For DM, the biomarker CRPM was positively correlated to MMT8, which agrees well with the 
fact that myositis appears to be associated with decreases in CRPM. Interestingly, and as seen 
for the correlations to IFN blood scores, the trends towards correlations observed in the PM 
group were inverse of those observed in the DM group.  
These data indicate that, if validated in larger cohorts, the neoepitope biomarkers could 
provide important information in relation to clinical trials.   
 
Limitations 
There are several limitations to our findings. Ideally, our biomarker panels should have been 
discovered in one cohort and validated in another, but the size of this trial was inadequate for 
that. We are intent on validating both the full and reduced biomarker panels in other myositis 
trials. 
Furthermore, we did not have MMT8 scores in the age- and gender matched controls. This 
would have been immensely useful to have to demonstrate that the biomarker relationships 
observed in myositis patients are related specifically to their pathologies and not a generic trait 
of the biomarkers. Additionally, no reliability measurement of the MMT8 raters was done in 
this study, and test-retest reference data for the MMT8 inventory are scarce in the literature, 
but a previous study with MMT hints at a test-retest reliability of 67-100 % in the hands of 
experienced raters across the various items, but an integrated reliability is not provided in this 
study [32]. However, these data indicate that an overall reliability of 80-90% should be 
expected, which agrees well with the reported reliabilities of similar manual measures [33]. 
Regarding the MMT8 score, many of the other papers in the literature about myositis 
biomarkers have correlated various wet biomarkers with pain scores in the form of muscle VAS 
[31,34]. In this study, we did not have access to muscle VAS scores. However, the muscle VAS 
score is also a subjective score with reliability in the same range as the MMT8 score. It must be 
considered that MMT8 integrates both a degree of pain measure, as pain compromises 
movement, and structural damage to or loss of muscle tissue. 
Finally, we did not take into account the potential effect of the glucocorticoid and/or baseline 
methotrexate therapy, and although a previous study showed that the IFN score was 
unaffected by this [20], it is of interest for future assessments of inflammatory biomarkers in 
myositis.  
Furthermore, we did not have MMT8 scores in the age- and gender matched controls. This 
would have been immensely useful to have to demonstrate that the biomarker relationships 
observed in myositis patients are related specifically to their pathologies and not a generic trait 
of the biomarkers. Additionally, no reliability measurement of the MMT8 raters was performed 
in this study, and test-retest reference data for the MMT8 inventory are scarce in the literature. 
Although a previous study with MMT hints at a test-retest reliability of 67-100 % in the hands 
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of experienced raters across the various items, an integrated reliability is not provided in this 
study [32]. However, these data indicate that an overall reliability of 80-90% should be 
expected, which agrees well with the reported reliabilities of similar manual measures [33]. 
Regarding the MMT8 score, many of the other papers in the literature about myositis 
biomarkers have correlated various wet biomarkers with pain scores in the form of muscle VAS 
[31,34]. In this study, we did not have access to muscle VAS scores. However, the muscle VAS 
score is also a subjective score with reliability in the same range as the MMT8 score. It must be 
considered that MMT8 integrates both a degree of pain measure, as pain compromises 
movement, and structural damage to or loss of muscle tissue. 
Finally, we did not take into account the potential effect of the glucocorticoid and/or baseline 
methotrexate therapy, and although a previous study showed that the IFN score was 
unaffected by this [20], it is of interest for future assessments of inflammatory biomarkers in 
myositis.  
 
Conclusion 
Thus, we can confirm that our biomarkers can help differentiate between DM and PM, an 
important feature, as it is attractive to treat the two forms of myositis with different regimens.  
We also found that neo-epitope biomarkers correlated with IFN gene score in blood for both 
PM and DM, and we found an indication of differential correlations to muscle function 
measured using the MMT8 inventory.  
Together, these findings suggest that biomarker panels consisting of ELISAs against Collagen 
type I and III fragments and MMP-degraded CRP are promising biomarkers in myositis in terms 
of diagnosis, functional characterization and likely monitoring of treatment efficacy. 
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5. BIOMARKER DEVELOPMENT, TARGETING INTRACELLULAR 
CONTRACTILE PROTEINS 
 
Title:  
Serum C-terminal slow skeletal troponin T as a possible biomarker of muscle wasting 
and rehabilitation 
 
Introduction to the cohorts:  
DAHANCA:  41 HNSCC patients that have been through radiotherapy with or without 
chemotherapy as well as a weight-, gender- and age-matched control group of 21 healthy 
individuals. The patients were subjected to a training regime of their choice for 12 weeks and 
then to progressive resistance training for 12 weeks more. Measurements of lean body mass 
(LBM) and blood collection took place at baseline right after progressive resistance treatment 
(PRT) (T0) right after the first part of training (T12) and after completion of the training period 
(T24). Serum samples were collected before, during and after the training period. 
BBR: 20 healthy young men underwent 8 weeks of strict bed rest. They were randomized into 
two groups, i.e. resistive vibration exercise group (RVE) and control (CTRL) groups. The RVE 
group was assigned to resistive vibration exercise 11 times per week. No exercise was 
performed in CTRL group. After 8 weeks of bed rest, subjects were re-ambulated and observed 
in the hospital for another 5 days. Serum samples were collected 2 days before bed rest (BDC-
2), in the bed rest procedure (BR+) and in recovery period (R+).  
Main findings 
DAHANCA:  TNNT1 levels were significantly elevated in the patient group compared to the 
control group, even before engaging in any form of physical activity. After engaging in physical 
training, the biomarker levels further increased through time, reaching a significant difference 
both compared to the patients baseline (T24vsT0, p<0.05 ) as well as to the control group (T1 
and T24 vs control, p<0.0001). 
BBR: There was a significant difference between the two groups in the bed rest stage that 
demonstrates a distinct response to the RVE counter measure.  The increased levels of 
circulating TNNT1 for the RVE group in this study could be explained by the unloading of 
troponin from the muscle.  During the remobilization stage, the TNNT1 levels were increased 
significantly in both groups in a very similar manner, compared to the baseline as well as the 
levels during the bed rest period. In day 28 of recovery were the maximum levels of TNNT1 
observed and by the time of training completion, the levels were almost returned back to 
baseline.  
 
Conclusions 
We have developed a robust and specific biomarker targeted at the C-terminus of Troponin T1.  
The biomarker demonstrated differences across the two studies. Part of the biomarker 
response could reflect a process in training. In the immobilization study, findings were in 
accordance with previous research
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Abstract 
A competitive enzyme-linked immunosorbent assay (ELISA) directed at the C-terminus of fast skeletal 
troponin T was developed (TNNT1). The biomarker was technically and biologically validated and further 
evaluated in two muscle wasting and rehabilitation models. Extraction of tissues confirmed expression solely 
in skeletal muscle. The clinical cohorts comprised cancer patients exposed to resistance training after 
radiotherapy and as well as subjects from a longitudinal bed rest study, with and without countermeasure 
followed by rehabilitation. In the cancer study, the ΤΝΝΤ1 was found to be significantly elevated compared 
to both the control group and the patient’s baseline levels. Additionally, there was a distinct pattern of serum 
levels of TNNT1 between patients with and without countermeasure under bed rest, followed by a distinct 
increase in serum during the remobilization period. This biomarker could hold the potential to demonstrate 
changes in the skeletal muscle under wasting conditions or training interventions.  
 
Keywords: biomarker, ELISA, troponin T, skeletal muscle, bed rest, cachexia, muscle wasting, TNNT1 
 
Background 
Skeletal muscle loss happens naturally during aging but under circumstances as cancer and radiotherapy it 
can be significantly accelerated 1,2. Muscle loss can also occur in the younger population as a primary 
component of a musculoskeletal disorder3 or as a secondary outcome of another disease, inactivity, injury or 
medication4. The changes in skeletal muscle caused by these pathologies or the counter effects from 
therapeutic interventions against them have been challenging to monitor. The methods regularly used to 
assess or diagnose changes after muscle damage include biopsies or isotope labeling5, Magnetic Resonance 
Imaging (MRI)  or Dual-energy X-ray absorptiometry (DEXA) scans, all of which have significant limitations 6–
9. 
 Serum biomarkers are widely applied as they are an easier and much cheaper approach in monitoring tissue-
specific alterations. Serum markers of skeletal muscle changes, creatine kinase (CK), creatinine myoglobin 
and lactate dehydrogenase have been broadly used, but they lack in specificity regarding the tissue of origin 
and there are doubts about their diagnostic significance10,11.   
No matter the trigger, muscle loss is a consequence of an imbalance between protein synthesis and 
degradation, accompanied by loss of structural integrity in the sarcolemma and changes in the extracellular 
matrix (ECM) 12,13. Quantitative changes in muscle protein metabolism, in combination with increased 
permeability of the sarcolemma can result in release of protein fragments into the circulation. The protein 
fragments generated due to the underlying pathology form a unique proteomic profile. This new distinct 
proteomic profile in serum is of interest, with respect to identifying biomarkers that can be used to monitor 
changes in muscle mass and integrity with better precision. Moreover, muscle pathologies can demonstrate 
preference in fast or slow twitch fiber types as It has been shown that certain diseases demonstrate a 
favoritism for specific fiber types 14,15.  Such information is lost when using markers that lack any fiber type-
specificity. Additionally, besides muscle wasting, different patterns in either fiber type have been observed 
during muscle regeneration. Matrix metalloproteinases that facilitate muscle reparation by resolving the 
collagenous fibrotic tissue (mainly MMP-9 and MMP-2) demonstrate differential expression and activity in 
fast- and slow-twitch rich muscles 16.  
In skeletal muscle, the troponin complex resides on the thin filament of the sarcomere and is composed by 
fast and slow fiber specific isoforms of TnI, TnC and TnT proteins, each serving different functionalities. 
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Overall the troponin complex together with tropomyosin bind directly to actin and regulate muscle 
contraction. Troponin as a biomarker, is mainly known in the form of the cardiac TnI isoform biomarker that 
has been in use for decades as the gold standard in monitoring myocardiac infarctions17 Specifically, TnT 
serves as the anchor of the whole troponin complex by binding to tropomyosin and the other troponins 
through the C-terminus. Calcium-dependent muscle contraction is inhibited by TnT by suppressing myosin 
ATPase activity inactivating fiber contraction. Mutations in TnT can cause cardiomyopathies or nemaline 
myopathy which is a rare congenital muscle disease characterized by general weakness and hypotonia18. 
Complete absence of troponin T diminishes the Ca2+ dependent activation, while deletions in the last 14 or 
28 aminoacids in the C-terminus lead to ATPase activity 19. Irrespectively to presence of Ca2 truncation of the 
C-terminus prohibits full muscle relaxation20. Exercise-induced damage has been shown to allow release of 
skeletal troponin I into the blood stream21. Presence of slow skeletal troponin T in serum can reflect training-
induced changes in muscle and more specifically the troponin complex or preferential modification caused 
in slow-twitch fibers.  
We have raised a monoclonal antibody using a decapeptide, which is unique to the sequence for the C-
terminus of the slow isoform of skeletal troponin T (hereon referred to as TNNT1), that was used to develop 
an ELISA assay. The biomarker was technically validated and applied in two different cohorts. In the first 
study, a group of head and neck squamous cell carcinoma (HNSCC) patients after radiotherapy was admitted 
to a resistance training program alongside to a control group that followed the same training regime. In the 
second study healthy young men were exposed to 56 days of bed rest, split in a group with resistance 
vibration exercise as a countermeasure and a group with no countermeasure at all. After the bed rest period 
both groups entered the same rehabilitation process for a period of 128 days.  
Overall, the aim was to develop a robust assay following the changes of the TNNT1 biomarker in serum 
samples. Furthermore, we wanted to determine if the biomarker could distinguish changes in the skeletal 
muscle brought on by injury, inactivity or intervention 
 
Materials and Methods 
Reagents  
All compounds and reagents mentioned are high purity chemicals, provided by widely recognized 
manufacturers. Most chemicals are from Merck (Whitehouse Station, NJ) and Sigma Aldrich (St. Louis, MO). 
The synthesized peptides used for monoclonal antibody production were provided from the Chinese Peptide 
Company, Beijing, China. 
Immunization procedure 
Six 4–6 week-old Balb/C mice were immunized subcutaneously in the abdomen with 200 μL emulsified 
antigen (KLH-CGG-GKGRVGGRWK, 50 μg per immunization), using Freund’s incomplete adjuvant. 
Immunizations were performed at two-week intervals until stable titer levels were obtained. At each 
bleeding, the serum titer was investigated and the mouse with the highest titer was selected for fusion. The 
selected mice were boosted intravenously with 50 μg immunogen in 100 μL 0.9% sodium chloride solution 
three days before isolation of the spleen for cell fusion. 
Fusion and antibody screening 
The fusion procedure has been described elsewhere22. Briefly, mouse spleen cells were fused with SP2/0 
myeloma fusion partner cells. The hybridoma cells were raised in 96 well plates and incubated in 37C 
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incubator. After 7-10 days, supernatants were screened using an indirect ELISA, while the biotinylated 
peptide Biotin-GKGRVGGRWK was used as a catcher peptide on streptavidin-coated microtitre plates 
Competitive ELISA description 
When not stated otherwise, all the ELISA assays used are based on competitive binding inhibition of the 
antibody to the coater. In brief, the coater is a biotinylated form of the standard peptide that interacts with 
the streptavidin-coated plate wells. On the incubation step the antibody is inserted in solution with the 
standard peptide or the serum sample. The standard peptide or the analyte existing in the serum sample is 
competing with the coater against binding to the antibody. In the consequent washing step only the excess 
of antibody that managed to bind to the coater will remain while the antibodies bound to the free peptide 
will be washed away. Inhibition of the signal translates to the existence of higher concentration of the analyte 
in the original serum samples. 
 
Characterization of clones 
Clones were tested against the selection peptide (GKGRVGGRWK), a non-sense peptide, and an elongated 
peptide (GKGRVGGRWKA). The clones with the best selection peptide inhibition were chosen for subcloning. 
Clone selection was done at least 3 times by limited dilution, then the supernatant of monoclones were 
purified using Protein G columns according to manufacturer’s instructions (GE Healthcare Life Science, Little 
Chalfont, and Buckinghamshire, UK). Isotyping of the monoclonal antibodies was performed using the 
Clonotyping System HRP kit, cat. no. 5300-05 (Southern Biotech, Birmingham, AL). Native reactivity and 
peptide binding of the monoclonal antibodies was evaluated by displacement of human serum, plasma and 
urine; rat serum and urine; and mouse serum, plasma and urine, in a preliminary competitive ELISA using 10 
ng/mL biotinylated peptide coater on a streptavidin coated microtitre plate and the supernatant from the 
growing monoclonal hybridoma. 
Assay protocol 
A 96-well streptavidin plate was coated with biotinylated synthetic peptide Biotin-GKGRVGGRWK dissolved 
in assay buffer (50 mM PBS, 1% BSA, 0.1% Tween-20, 4g/L NaCl, pH 7.4 adjusted at 20°C) and incubated 30 
min at 20°C. 20 µL of standard peptide or sample were added to appropriate wells, followed by 100 µL of 
monoclonal antibody and incubated overnight at 4°C. Then, 100 µL of Horse radish peroxidase (HRP) 
conjugated rabbit anti-mouse polyclonal antibody solution (Jackson immunoresearch, Baltimore USA, 
product code: 315-035-045) were added, and the plate was left to incubate at 20°C for 1h. Finally, 100 µL 
tetramethylbenzinidine (TMB) (Kem-En-Tec cat. no. 438OH) was added and the plate was incubated 15 min 
at 20°C in the dark. All the above incubation steps included shaking at 300 rpm. After each incubation step 
the plate was washed five times in washing buffer (20 mM Tris, 50 mM NaCl, pH 7.2). The TMB reaction was 
stopped by adding 100 µL of stopping solution (1% HCl) and measured at 450 nm with 650 nm as the 
reference. A standard curve was produced through a serial 1:2 dilution of the calibrator decapeptide and 
plotted using a 4-parameter fit mathematical fit (y =(A-D)/(1 + (x/C^B) + D)) model in Softmax Pro version 6.3 
(Molecular Devices, Sunnyvale, CA, USA). The fit was used to calculate the analyte level in all samples and 
controls through curve regression. 
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Technical evaluation 
Human and rat serum quality control (QC) samples were used to determine dilution recovery from 2-fold 
dilutions. Linearity was calculated as a percentage of the serum recovery values from the undiluted sample. 
The lower limit of detection (LDL) was estimated by running 21 blank samples (assay buffer) and determined 
as the mean+3xSD. The inter and intra assay variations were determined by running 10 independent assay 
runs with 5 QC samples, in three different days and in different time points. All sample assessed in every 
assay run were in double determination. 
Tissue lysate preparation 
Rat tissues from heart, brain, soleus and extensor digitorum longus were snap-frozen in liquid nitrogen and 
pulverized using mortar and pestle. The residue was transferred to a vial and weighted. Extraction buffer 
was added (250mg tissue/mL buffer). For clearing the lysate, 5-6 shots of 5 sec sonication each every 10 
min were applied until the lysate was homogenous. In between the lysate was kept on ice. After sonication 
the debris was span down at 4°C /15 min / 13000rpm – supernatant was collected and stored at -80°C.  
Extraction buffer: 50mM Tris-HCl (Sigma Aldrich cat T3253) 50mM HEPES (Sigma Aldrich cat H3375) 15% 
glycerol (Merck cat 1.04094) 1mM EDTA (Merck cat 1.08418) 0.5% sodium deoxycholate (Sigma Aldrich cat 
D6750) final pH 8.3 -plus the protease inhibitor cocktail (from Roche, cat no 05 056 489001), 1 tablet to 50 
ml buffer (Stored at 2-8°C). For protein determination the DC Protein Assay from BioRad was used and 
protein concentration was adjusted before tested in the ELISA assay. 
 
Clinical samples 
The Danish Head and Neck Cancer Group (DAHANCA) 25B trial 
Patient plasma samples and data obtained from the DAHANCA 25B randomized controlled trial (RCT) 
(registered clinicaltrials.gov identifier: NCT01509430) were used for this analysis. The DAHANCA 25B is 
described in full detail  elsewhere23. Briefly, the trial involved 41 HNSCC patients that have been through 
radiotherapy with or without chemotherapy as well as a weight-, gender- and age-matched control group of 
21 healthy individuals which were included and described in a previous study (Lønbro et al., 
https://www.ncbi.nlm.nih.gov/pubmed/23964657) . The patients were randomly assigned to 12 weeks of 
progressive resistance exercise initiated either immediately after the two-month post-treatment follow-up 
(EE group) or initiated with a 12-week delay (DE group). Radiotherapy and chemotherapy was conducted 
according to the DAHANCA guidelines (www.dahanca.dk) at the oncological departments of Aarhus 
University Hospital and Odense University Hospital. The exercise protocol comprised 2-3 weekly session with 
seven exercises addressing the large muscle groups of the body. . Assessments of lean body mass (LBM) and 
blood collection took place at baseline before the initiation of progressive resistance training (PRT) (T0), just 
after the first 12 weeks of PRT completion of the EE group with the DE group acting as controls (T12) and 
again after the last 12 weeks of PRT completion of the DE group with the EE group acting as controls (T24).  
All blood sampling, testing and training took place and repeated at the same local facilities for each patient. 
Lean body mass was found to be increased equally by approximately 4.3% in both the EE and DE groups after 
PRT. Collective data from the patient and control groups at baseline can be seen in Table 1.  
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Table 4: Anthropometric measurements of the subjects involved in the DAHANCA study. 
  Cancer patients Controls Cancer stage   
n 41 21 N/A 7 (17%) 
Age (years) 56+7 59+6 1 4 (10%) 
Gender (M/F) 36M/5F 14M/7F 2 4 (10%) 
Weight (kg) 72.7+13.7 76.3+13.2 3 4 (10%) 
Height (m) 1.76+0.08 1.77+0.09 4 22 (54%) 
BMI (kg/m2) 23.4+3.6 24.4+3.1   
LBM (kg) 53.2+8.7 54.9+12.5   
 
 
Berlin Bed Rest study 
The study has been described elsewhere24. Briefly, 20 healthy young men underwent 8 weeks of strict bed 
rest. They were randomized into two groups, i.e. resistive vibration exercise group (RVE) and control (CTRL) 
groups. The RVE group was assigned to resistive vibration exercise 11 times per week. Vibration resistance 
exercises were performed by installing a vibration exercise apparatus at the end of the beds and pulling the 
subject towards the vibration plate with waist and shoulder straps and handles for the subjects to pull 
themselves towards the plate. No exercise was performed in CTRL group. After 8 weeks of bed rest, subjects 
were re-ambulated and observed in the hospital for another 5 days. The serum samples were collected 2 
days before bed rest (BDC-2), in the bed rest procedure (BR+) and in recovery period (R+). Serum was thawn 
from −80 °C and TNNT1 was measured. The muscle mass of both groups were assessed by MRI and DEXA 
during the three periods. The study was approved by the ethics committee of the Charité Universitätsmedizin 
Berlin. Subjects gave their written informed consent 
 
Statistical analyses   
 
The biomarker data measured in the two clinical studies were initially subjected to a distribution analysis in 
order to determine whether any transformation was necessary. Where significant group effects were seen, 
manual testing, subjected to Bonferroni correction was performed. The analysis of variance was performed 
in Prism (v6.00 for Windows). Mean values and standard error of the mean (SEM) were calculated using 
GraphPad Prism, version 6 (GraphPad Software, San Diego, CA, USA). Subject values were analyzed using 
ordinary one- or two- way analysis of variance test appropriately, with Bonferroni correction for multiple 
comparisons. 
Biomarker data from the control group and the HNSCC subjects were compared at baseline in a mixed models 
analysis of variance. In this analysis, all HNSCC subjects were pooled, as they were not separated by different 
intervention courses yet and thus biologically comparable. 
 In the BBR study Data were organized and transformed accordingly in Microsoft Excel for Windows 
(Microsoft Corporation, Redmond, WA, USA). Then the data were subjected to mixed models repeated 
measures ANOVA analysis, testing for Time and Treatment (CTRL vs. RVE) effects as well as Time*Treatment 
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interactions. If main effects were present, appropriate post hoc tests were performed, subjected to 
Bonferroni correction for multiple testing. Significance threshold is determined to be p<0.05 and data are 
presented as means ± SEMs where relevant. 
 
Results 
Technical performance 
The lower limit of detection (LDL) for the assay was 0.63 ng/mL. Dilution recovery was within the acceptable 
range 100 ± 15% for human serum (overall mean 99.3%, Table 2) and the linearity followed closely the 
standard curve (Fig 1). The inter- and intra-assay variation was around or below 10% for assessments in both 
assays.  
 
 
Table 5: Dilution recovery calculation in 5 serum samples  
 HS-41 HS-60 HS-53 HS-71 HS- 89s 
Undiluted 100% 100% 100% 100% 100% 
1:2 Dilution 103 100 105 99 98 
1:4 Dilution 96 89 104 99 99 
1:8 Dilution 90 89 117 97 104 
Mean 96 93 108 98 100 
 
 
Figure 4: Linearity test between the standard curve and the serial dilutions of human and rat serum.  
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Rat muscle extracts 
Extractions of rat tissues from three different animals were used to gauge skeletal muscle and isoform 
specificity of TNNT1. Type I fibers constitute about 96% of the soleus muscle (SOL), while extensor digitorum 
longus muscle (EDL) only contains 5.5% Type I fibers25. Heart was also tested for cross-reaction, while 
recombinant troponin T1 protein and rat brain extractions were used as a positive and negative control 
respectively. In figure 2 we observed as expected that the TNNT1 levels measured in SOL were much higher 
than EDL, while no signal was obtained in heart and brain tissue extracts. 
 
Figure 5: TNNT1 values as measured in tissue extractions from rats. Extraction buffer reported mean value was subtracted by all 
values. Soleus consists mainly of type I fibers while there is much less expression of type I fibers in the EDL The epitope was not detected 
in heart and brain lysates that were used as negative controls. 
 
Clinical studies evaluation 
DAHANCA 
HNSCC patients are known to lose lean body mass consequently to both their disease and therapeutic 
intervention, forming a representative group where muscle turnover has been altered26. In the DAHANCA 
25B trial, HNSCC patients that have underwent radiation with or without chemotherapy were assigned to 
progressive resistance training in order to recover from the muscle loss that they experienced as a secondary 
effect to the pathology or treatment23. During rehabilitation an average of 4.3 % regain of LBM was observed 
between the different timepoints, following progressive resistance training. By measuring the TNNT1 
biomarker in this study, we aimed at monitoring the effect both the impact of the pathology and treatment 
of the patients at baseline compared to the control group, and of training regime through the different time 
points. Since no differences in TNNT1 serum levels were observed between the EE and DE groups following 
PRT, all patients were pooled together in one group for time points T0, T12 and T24.  
As demonstrated in fig. 3 TNNT1 was found elevated in serum samples obtained right after treatment, 
compared to the control group (T0, p=0.0124). Furthermore, TNNT1 was significantly increased at both time 
points under training compared to the control group (T12 and T24, p<0.0001). Within the training period, 
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TNNT1 levels in serum were found progressively increased compared to the patients baseline with a 
significant difference between T24 and values at baseline (T24 p<0.05 compared to T0, marked with #).  
 
  
Figure 6: Serum sample measurement results from the DAHANCA study. Patient samples were retrieved at baseline (T0) before any 
training and at 12 weeks (T12) and 24 weeks (T24) later in the training regime. Significance to the control group is denoted by “*” 
while significance to the patient baseline is denoted by “#” 
 
Berlin Bed Rest (BBR) 
Prolonged periods of inactivity of the lower limbs during space flight missions or bed-rest have shown a 
negative impact to muscle mass as determined by DEXA and MRI imaging24.  Significant muscle loss has 
occurred during bed rest studies but many different countermeasures have been tested for their potency as 
protective remedies 27,28. Muscles that have a predominance of slow twitch fibers have demonstrated higher 
wasting rates during disuse in both rat human studies13,29. Resistance vibration exercise has been proposed 
as a good method of countering the muscle loss in extensive bed rest periods. The hypothesis of testing the 
levels of TNNT1 in a longitudinal bed rest study with and without counter-treatment is that there will be a 
difference, both between the two groups and between the different time points as changes in muscle occur24.   
Serum concentration of TNNT1 increased gradually initially up to 13.7% from baseline (± 5.53, BR26) and 
remained elevated throughout the bed rest period for the RVE group (fig 4). In contrast, the CTRL group had 
a marked drop in the first two weeks of immobilization, down to -7.12% (±2.11, BR5) before returning to 
normal levels by the end of the bed rest period. In the initial stages of bed rest, the difference between the 
CTRL and RVE groups was significant, reaching the highest separation at BR5 (CTRL vs RVE, p=0.0005). During 
the recovery stage, a significant increase of TNNT1in serum was observed in a very similar pattern for both 
the groups, which then returned to almost normal levels for both groups by the last day of recovery (Peak 
points: +32.97 ±4.98% for CTRL R28, p=0.0037 and 30.53 ±4.18% for RVE, p=0.0048).   
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Figure 7 Comparison of the two different groups participating in BBR throughout the different time points. BR indicates the timepoints 
in the bed rest period of lower limb immobilization while R indicates the remobilization period timepoints measured in days. A 
distinctive pattern is observed between the control and RVE groups in the bed rest period indicating changes caused by the RVE 
countermeasure. This difference reached the highest point in BR5 where the TNNT1 serum levels were most significantly different 
(p=0.0005, noted with ###)  In the recovery stage the response to remobilization is almost identical throughout the whole period. The 
levels of TNNT1 were significantly different for both groups compared to the baseline.  
 
Discussion 
Biomarkers reflecting muscle turnover, gain or loss are of big interest regarding diseases that affect muscle 
synthesis/degradation equilibrium as well as therapeutic interventions. Very few serum protein biomarkers 
have been strongly connected to those processes in human studies 30,31. Notably, it has been shown that 
troponins can be released in both muscle specific pathologies and interventions32–34. We have developed an 
assay specifically directed at the C-terminus of the slow isoform of troponin T, TNNT1 to investigate its validity 
as a serum biomarker for changes in skeletal muscle.  
Tissue specificity  
Our analysis of the expression of TNNT1 in various tissues indicated that it is specifically expressed in skeletal 
muscles, whereas heart and other tissues appear not to express TNNT1 at detectable levels. This is consistent 
with previous findings on TNNT1 14,15, and indicates that serum levels of TNNT1 will reflect changes in skeletal 
muscle.  
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DAHANCA Head and neck squamous cell carcinoma (HNSCC) 
In order to assess the TNNT1 biomarker for a possible response to changes in catabolism/anabolism, we 
measured samples from HNSCC patients that after radiation treatment participated in muscle training 
rehabilitation. HNSCC patients are known to lose lean body mass as a consequence of both their disease and 
therapeutic intervention, forming a representative group where muscle turnover has been altered26. In the 
DAHANCA 25-b study, HNSCC patients that have underwent radiation with or without chemotherapy were 
assigned to progressive resistance training in order to recover from the muscle loss that they experienced as 
a secondary effect to the pathology or treatment. By applying the TNNT1 biomarker in this study, we aim at 
monitoring the effect of both the impact of the pathology and treatment of the patients at baseline compared 
to the control group, and of the training regime through the different time points 
In this study we assessed the levels of TNNT1 in serum samples obtained by HNSCC patients at baseline right 
after primary treatment and at two follow-up time points when the patients underwent resistance training. 
Additionally, biomarker levels were measured in an age- and weight-matched healthy control group that did 
not participate in any training or physical activity. The purpose of this was to evaluate TNNT1 as a biomarker 
of response to changes in skeletal muscle.  
We found that TNNT1 levels were significantly elevated in the patient group compared to the control group, 
even before engaging in any form of physical activity. It is known that cancer patients can sustain increased 
muscle degradation even after therapy. However, in this study it cannot be determined whether the 
amplified release of TNNT1 in the blood stream is a result of the catabolic state of the patients or of an 
increased protein turnover due to the disease or the treatment.  
After engaging in resistance training, the biomarker levels further increased, reaching a significant difference 
both compared to the patients baseline (T24vsT0, p<0.05 ) as well as to the control group (T12 and T24 vs 
control, p<0.0001). This steady increase reflects a response to the resistance training independent of the 
disease and/or the treatment. During the training period of 24 weeks, patients gained an overall average of 
4% in LBM as it has been described in previous papers (refs). This increase in LBM  was accompanied by 
changes in biomarkers of MMP-based collagen turnover in the ECM35. The combination of the anabolic effect 
and increased turnover due to the training alongside to the ECM remodeling set the basis for the changes of 
TNNT1 as well. At this point unfortunately it is not feasible to isolate a precise origin for the biomarker 
changes.  
 
Berlin Bed rest study (BBR) 
Prolonged periods of inactivity of the lower limbs during space flight missions or bed-rest have shown to have 
a negative impact on muscle mass as determined by DEXA and MRI imaging24.  Significant muscle loss has 
occurred during bed rest studies. Different methods have been tested for their potency as protective 
remedies was assessed27,28. Muscles that have a predominance of slow twitch fibers have demonstrated 
higher wasting rates during disuse in both rat human studies13,29. Resistance vibration exercise has been 
proposed as a good method of countering the muscle loss in extensive bed rest periods. The hypothesis of 
testing the levels of TNNT1 in a longitudinal bed rest study with and without counter-treatment is that there 
will be a difference, both between the two groups and between the different time points as changes in 
muscle occur. 24 
We observed that in the initial stages, the RVE and CTRL groups followed a different trend. The serum levels 
of TNNT1 in the RVE group were elevated from the baseline, while the levels in the CTRL group initially 
[67] 
 
decreased before reaching back to the baseline. The significant difference of the two groups in the bed rest 
stage (BR5 CTRL vs RVE, p=0.0002) demonstrates a distinct response to the RVE counter measure, regarding 
release kinetics of TNNT1 to the blood stream. It is documented that eccentric training is related to muscle 
injury and fiber type preferential damage, leading to release of protein fragments, including troponins, in 
blood circulation 33,36,37. Repeated bouts of eccentric contractions under RVE training may be a confounding 
parameter for the elevated increase of TNNT1. In the CTRL group the initial drop could possibly be explained 
by the inactivity of the lower extremities and the lack of any countermeasure. It is not clear what the reason 
is for the later recovery and fluctuation in the TNNT1 levels during the bed rest process. There is the 
possibility that the TNNT1 releases into the bloodstream due to the followed atrophy and total muscle 
degradation induced by the complete inactivity. Unfortunately no specific dietary program was followed and 
food intake was not monitored to exclude the possibility of under-nutrition as a probable cause of atrophy 
in either BBR studies. In BBR-2 within the type I-rich SOL muscle the levels of TNNT1 were increased but were 
decreased in VL. This differential expression between the miscellaneous leg muscles in the CTRL group could 
be the reason for the variable pattern before the recovery stage.  
In addition to the BBR study we used 24, in a very similar study named BBR2 the group of Salanova et al have 
demonstrated the changes in the muscle fiber composition and protein contents 38. They divided the 
participants into three groups that had RVE training, resistance training or no counter measures and obtained 
biopsies from soleus and VL muscles at baseline and after 60 days of bed rest. According to their findings, 
there was a decrease in the size of type I fibers in the CTRL group for both SOL and VL, while the RVE group 
maintained fiber size. Additionally, there was a clear drop in the total number of type I fibers between the 
two biopsies for the CTRL group while in the RVE the negative change was not as pronounced. However, 
based on 2D DIGE quantification, TNNT1 was found in lower levels in the end biopsies of both muscles for 
the RVE group, while for the CTRL group it was increased in SOL but decreased in VL. In combination with 
their results, the increased levels of circulating TNNT1 for the RVE group in this study could be 
consequentially explained by the unloading of troponin from the muscle 
During the remobilization stage, the TNNT1 levels were increased significantly in both groups in a very similar 
manner, compared to the baseline as well as the levels during the bed rest period. In day 28 of recovery were 
the maximum levels of TNNT1 observed and by the time of training completion, the levels were almost 
returned back to baseline. This common peak depicts that the biomarker reflects a response triggered by 
training. Various publications support the skeletal troponin release during training34,39. In previous 
publications collagen and titin biomarkers were applied in the same BBR study. Collagen III formation 
biomarker (Pro-C3) has demonstrated direct correlation with changes in LBM. The release pattern or Pro-C3 
during the bed rest was very similar to TNNT1 in the control group, possibly indicating a close relation to the 
release of the TNNT1 and changes to the LBM 40. The MMP-2 cleaved titin biomarker also followed the same 
initial decrease, again depicting the disuse-induced initial atrophy 41.  
The pattern of the TNNT1 release kinetics does not seem to follow a clear anabolic or catabolic stimulus and 
in some cases the possibility for this could be masked by changes due to damage from eccentric exercise. In 
catabolic conditions, caspase-3 has been found to be activated in skeletal muscle, assisting to the degradation 
through the ubiquitin-proteasome system42. Caspase-3 activation produces a characteristic fragmentation of 
actin, while it has also been found to have a cleavage point in TnT that is conserved in the slow skeletal 
isoform43. This mechanism could at least partially explain the release of TNNT1 with no involvement of muscle 
injury in the case of cachexia in the cancer patients and the control group in the resting period in the BBR. As 
pointed out in the introduction, truncation of the C-terminus of TnT leads to inability of complete muscle 
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relaxation which can be associated to poor grip strength. It would be very interesting to test if progressive 
accumulation of TNNT1 in patients of muscle wasting can also correlate to changes in grip strength.  
Limitations  
Although the differences between the levels of TNNT1 are interesting, the study design does not allow for a 
pinpoint explanation regarding the kinetics or release mechanism into the blood stream. Both studies are 
also very small in number of participants which imposes the need of validation of the biomarker in a more 
extensive cohort. Furthermore, in the BBR study even though the patients were not using their lower limbs 
during the immobilization, they were compensating with their upper body for all the daily movements. Since 
no data were available for the changes in muscle of their upper torso and extremities, the total levels of the 
biomarker measured in serum could be a consequence of a mixed phenomenon rather than originating 
purely from the lower limbs.  Moreover, when comparing with the results obtained from 2D gels from other 
studies, it needs to be kept in mind that those assays do not at all measure the same thing. In the gel system 
only the full protein can be identified while our assay targets the C-terminal part of TNNT1 which would 
indiscreetly measure the whole protein and/or any fragments that would include the epitope.  
Conclusion and future perspectives 
We have developed a robust and specific biomarker targeted at the C-terminus of Troponin T1. The assay 
was tested in two different cohorts, a study of HNSCC patients with resistance training in rehabilitation after 
treatment and a second immobilization study with and without training countermeasure. In both studies, we 
have observed significant changes in the biomarker levels in serum compared to baseline and the respective 
control groups. In both studies during the recovery stage after muscle loss or muscle atrophy, elevation of 
the biomarker was observed in serum.  This increase could be attributed to an increased turnover during the 
recovery or to a response to the exercise. Furthermore, during the immobilization stage of the BBR study, a 
different pattern was observed between patients with training and the control group. The differences could 
be explained based on previous findings from other groups regarding the TNNT1 content in biopsies obtained 
during a similar immobilization study. Based on the collective findings we could not relate the biomarker to 
a specific anabolic or catabolic process as we have no clear indication for the mechanisms that it reflects 
regarding the protein turnover during training. As mentioned, one of the very interesting aspects of the 
fragmentation in the c-terminus of TnT is the impact on the proper muscle contraction and force generation. 
A very relevant disease for TNNT1 to be tested for its clinical significance, could by myotonic dystrophy (DM) 
which has a unique pathology associated with general stiffness and difficulties in relaxation of grip44. In 
addition to signs of possible dysregulation of the troponin system, myotonic dystrophy has also demonstrate 
profound selective atrophy of type I muscle fibers and isotype shifting. 
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6. GENERAL DISCUSSION  
 
 
Skeletal muscle is a very important tissue and constitutes 40% of the total bodyweight of an 
average adult human. It is important for structure, support, motion functionality and proper 
metabolism within a healthy organism. When affected by pathologies or diseases there are 
three main manifestations: continuous inflammation, progressive fibrosis and gradual muscle 
wasting. Since some of the muscle diseases have no cure available, a lot of effort has been put 
towards therapeutic interventions that can prevent or reverse these symptoms.  
In inflammatory myopathies, excessive activation of inflammatory pathways and accelerated 
muscle degradation have been connected to overexpression of MMPs 165.  Targeted inhibition 
of the cytokines involved in the abnormal protease activation, e.g.  TNF-α, IL-2, IL-6, has shown 
potential as treatment in inflammatory myopathies and dystrophies 161–164. Administration of 
glucocorticoids is recommended as first-line treatment as it can slow down loss of locomotor 
function or even provide temporary improvements 157–160.  
Fibrosis in the endo- and per-mysium is caused by accumulation of  collagen I, III, IV and 
fibronectin 148,149. In DMD, endomysial fibrosis has been one of the strongest predictors of 
motor function deterioration. Inhibiting fibrosis may improve muscular function, which is the 
purpose of several current and preceding pharmacological trials. Previous preclinical and in 
vitro studies have documented that myostatin inhibitors downregulate markers of fibrosis, but 
this has not been shown conclusively in clinical models yet 150,151. The most advanced in terms 
of clinical trials is HT-100, a delayed-release Halofuginone preparation. It exerts its effect 
through inhibition of fibrosis and inflammation, in part through blocking of TGF-beta signalling 
197, while it also directly inhibits collagen type I synthesis.  At the time of writing, the drug has 
entered Phase II trials for DMD  (by Akashi, NCT02525302), overseeing improvements in muscle 
function and gain. Other pharmaceutical approaches aimed at restoring functional muscle mass 
are under examination. Anabolic drugs have shown some promise, although none of these have 
reached FDA approval yet. Inhibition of myostatin has been shown to result in muscle 
hypertrophy and myostatin inhibitor drugs are at the time of writing in clinical trials for myositis 
(Novartis’ bimagrumab in phase II completed in Feb 2017, NCT01423110) and Duchenne (PF-
06252616 for Pfizer, phase II, NCT02310763). 
 
Unfortunately, there is still an unmet need of monitoring tools directed at the progression of 
these manifestations. Progression rates regarding the disease itself or the response to the 
treatment could possibly be monitored with imaging or anthropometric methods but 
biomarkers that are more sensitive could provide faster assessment, biomarkers that have 
been widely used have not demonstrated clinically the required specificity in following the 
trajectory of these processes. No single biomarker has been effective and it is possible that a 
panel of biomarkers would be more capable of describing these complex symptoms.  
 
Qualitative or changes in in muscle strength or function can be identified early, by monitoring 
fibrosis and inflammation within the muscle tissue through an array of serum biomarkers. 
Biomarkers have been successful in providing information for developing therapies during 
antifibrotic clinical trials. Biomarker characterization in a Halo/Akashi trial of Halofuginone 
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helped reveal fibrosis-collagen turnover, incidentally through use of fibrotic neoepitope 
collagen biomarkers, i.e. PINP and C3M. 
 
The main objective of the thesis was to develop, characterize and test protein fingerprint 
biomarkers reflecting changes in muscle, resulting from different pathologies or conditions. 
One part of the objective was to test the potential of already existing biomarkers aiming at 
specific mechanisms involved in muscle pathologies. The other part was to develop a new 
biomarker based on a muscle protein with a structural as well as functional role in human 
skeletal muscle. 
More specifically, we aimed at (1) assessing biomarkers aiming at the ECM for their ability to 
describe the common processes of the most muscle pathologies: inflammation and fibrosis. 
Then we selected troponin T1 as a candidate protein and aimed at (2) developing an ELISA assay 
targeting the C-terminus of troponin T1 (TNNT1). After validating the assay, we applied the 
TNNT1 biomarker in on one study involving patients under severe muscle loss and a second 
study where they were forced to inactivity that led to progressive atrophy. Both studies 
involved a rehabilitation period with exercise. The aim in those two studies was (3) to 
determine if TNNT1 is released from within the muscle fibers into the blood circulation and 
able to be measured, and (4) to test if the release kinetics can be identified and associated with 
a physiological process of the disease or the training intervention.  
 
6.1. Assessing biomarkers aiming at the ECM for their ability to describe the 
common processes of the most muscle pathologies: inflammation and fibrosis 
Idiopathic inflammatory myopathies are a group of, acquired systemic diseases that are 
characterized by elevated serum levels of muscle enzymes, inflammatory infiltrates and lead to 
progressive muscle weakness. Dermatomyositis (DM) and polymyositis (PM) are two very 
similar inflammatory myopathies, distinguished only by the involvement of the skin in DM 
pathology. 
Here we present data indicating that differential diagnosis of PM and DM can be obtained using 
collagen turnover biomarkers. Furthermore, in this small study we were able to identify 
relationships between the biomarkers and both inflammatory indicators, such as IFN score in 
blood, as well and the functional score MMT8. Data, which clearly indicate that the collagen 
turnover biomarkers are of relevance when developing therapies for the different forms of 
myositis.  
 
6.1.1: ECM fingerprint in inflammation  
As expected, ECM biomarkers of formation and degradation were detected in serum samples 
of IIM. The biomarker levels were found to be significantly different both within the two 
myositis as well as compared to the control group. In detail, both types of myositis were 
associated with substantial decreases in PINP biomarkers compared to controls, while 
increased levels of PRO-C3, C1M and C3M were associated only with DM.  
Collagen I formation marker PINP in both myositis matched the findings of a previous study in 
which the C-terminal fragment of collagen type I was on the contrary upregulated 189. Both of 
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the markers are associated with synthesis and maturation of collagen I, which complicates a 
straightforward conclusion regarding the turnover process that they reflect. Although a trivial 
explanation would be that the biomarker decrease reflects a decrease in collagen I synthesis, 
in the Kubo study, polymyositis patients have shown increases in the amount of collagenous 
tissue, e.g. fibrosis 190. This does not necessarily contradict our findings, as fibrosis is associated 
with not just increased amounts of collagenous tissue, but also qualitative changes in turnover 
168,172. Moreover, the disease can consist of different stages where fibrosis is not always actively 
ongoing, where collagen biomarker levels can depend on the sole sampling time point in a cross 
sectional study.  
Increased degradation of collagen I as determined by C1M levels was only observed in DM. 
Similarly, C3M was found to be elevated in DM but not in PM. As described before, the major 
distinction between DM and PM is the involvement of skin in the pathology of DM. Collagens 
type I and III, are major constituents of the skin, which could explain the upregulation of those 
specific collagen types turnover in DM, but this needs to be verified experimentally. Our 
findings could be verified in a case study conducted using an old assay measuring the pro-
peptide of collagen type III. Myositis patients compared to control values showed increased 
levels of the biomarker here191.  
In other inflammatory conditions such as rheumatoid arthritis and in subgroups of 
osteoarthritis patients, increased CRPM has been described as a biomarker of local 
inflammation 85,181. Despite myositis being characterized by inflammation and heightened MMP 
activity, in this study CRPM was surprisingly decreased for both DM and PM, relative to healthy 
subjects. This could be in agreement with the assumption that parts of the disease were not 
active at the time of sampling as with the case of collagen I markers. It is also possible that the 
MMPs that are responsible for the fragment generation of CRP198 are different than the ones 
accountable for the inflammatory status in myositis. If not so, further elucidation of the 
mechanisms involved in the progression of the disease would be required.   
No matter what, the ECM fingerprint clearly demonstrated the potential to demonstrate 
differences in the collagen turnover between DM and PM, more so beyond the obvious 
distinction from the control group. Implementation of these biomarkers to a more extensive 
cohort would be very interesting, especially one that can provide info regarding anti-
inflammatory treatment response.  
6.1.2. Neoepitope biomarkers vs. IFN gene signature 
As the IIMs are inflammatory by definition and PM and DM are responsive to anti-inflammatory 
treatments. One of the extensively used biomarkers in recent years is the interferon gene 
signature since it has been shown to correlate (R2 of 0.3-0.4) with global and muscle-specific 
soreness as well as several other myositis biomarkers 193. Comparison between the trends in 
ECM biomarkers and IFN gene signature allowed the assessment of the neoepitope biomarkers 
as markers of disease activity.  
Interestingly, in the PM group C3M which is considered to be a marker of systemic 
inflammation, showed a borderline significant correlation in PM (Spearman’s r=0.4, p=0.056) 
with the IFN score in blood, as did CRPM and C6M. In DM, C3M demonstrated a significant 
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correlation (Spearman’s r=0.4, p<0.05) with IFN score in blood, but neither CRPM nor C6M did. 
In fact, in DM, C6M marker was inversely correlated to IFN score in blood in DM, albeit not 
reaching statistical significance.  
These data support the claim of neo-epitope biomarkers providing differential output in the 
two myositis groups, and potentially indicating that, if validated carefully, markers such as C3M 
could replace the need for IFN gene scores.  
6.1 3. Neoepitope biomarkers correlate with MMT8 score 
In this study, we correlated the biomarker levels to MMT8 (Manual muscle testing) 
measurements obtained, in order to find out if there was any relationship with the functional 
status of the subjects in the form of the MMT8 measurement obtained in this study. In DM, 
there was a positive correlation observed between CRPM levels and MMT8, which is in good 
accordance with the fact that myositis appears to be associated with decreases in CRPM. It is 
Interesting, that PM follows opposite trends from DM in the case most biomarkers to MMT8. 
This pattern was also observed in correlations to IFN blood scores.  
Table 6: (Taken from manuscript II) Spearman’s r correlation coefficients for the biomarkers, the IFN scores 
and the muscle output. 
 C1M PINP C3M  Pro-C3 CRPM C6M 
DM IFN Blood 0.002  0.33  0.40* -0.02  0.32 -0.18 
IFN Muscle -0.18  0.10  0.14  0.15 -0.03 -0.27 
MMT8 -0.01 -0.17  0.38 -0.03  0.46*  0.21 
PM IFN Blood  0.24  0.11  0.40  0.25  0.45*  0.42* 
IFN Muscle  0.05  0.04  0.16  0.22  0.12  0.13 
MMT8 -0.20  0.01 -0.36 -0.34 -0.37 -0.38 
 
These data indicate that, if validated in larger cohorts, the neoepitope biomarkers could 
provide important information in relation to muscle strength and possibly functionality. The 
clearly different levels and correlation patterns regarding the ECM biomarkers, among two very 
similar diseases is encouraging in the pursuit of defining minute changes in such pathologies.  
 
6.2. Developing an ELISA assay targeting the C-terminus of troponin T1 (TNNT1) 
 
Contractile protein based biomarkers reflecting muscle turnover, gain or loss are of big interest 
regarding diseases that affect muscle synthesis/degradation equilibrium as well as therapeutic 
interventions. There is a limited amount of such protein biomarkers strongly connected to 
those processes in human studies, but still none of them has been established clinically 136,142. 
Troponins are known to be able to release in both muscle specific pathologies and 
interventions199–201. We have developed an assay specifically directed at the C-terminus of the 
slow isoform of troponin T, TNNT1 to investigate its validity as a serum biomarker for changes 
in skeletal muscle. The assay was validated technically for its specificity and robustness before 
being applied to two clinical cohorts. Using muscle lysates and control tissue, we demonstrated 
that the biomarker was muscle specific. We found that our biomarker could indeed be detected 
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in blood circulation in relation to muscle damage. The results presented in manuscript III will 
be discussed separately for the two studies.  
 
6.2.1 TNNT1 serum levels in Head and neck squamous cell carcinoma (HNSCC) 
intervention study (DAHANCA)  
 
HNSCC patients provided a good study system for afflicted protein turnover, as a consequence 
of both their disease and irradiation treatment, possibly under a state of cachexia 202. Patients 
that have undergone radiation with or without chemotherapy were assigned to progressive 
resistance training in order to recover from the muscle loss that they experienced203,204. Amidst 
muscle regain, the anabolic stimulus following the catabolic state was the basis of our interest 
in applying the TNNT1 biomarker in this study.   
Indeed, TNNT1 levels were significantly elevated in the patient group compared to the control 
group, at baseline. However, within the study design it is impossible to claim if amplified release 
of TNNT1 in the blood stream is a result of the catabolic state of the patients or of an increased 
protein turnover due to the disease or radiation.  
After engaging in physical training, the biomarker levels further increased through time, 
reaching a significant difference both compared to the patients baseline (T24vsT0, p<0.05 ) as 
well as to the control group (T1 and T24 vs control, p<0.0001). The elevation of TNNT1 in 
response to resistance training was independent of the disease and/or the treatment. Although 
patients gained an overall average of 4% in LBM, we could not find a correlation between that 
gain and TNNT1 levels. It is more probable that TNNT1 follows an anabolic stimulus under 
training or an increased turnover because of the nature of the exercise. A higher turnover 
concurrently with the  increase in lean mass  is in accordance with the findings regarding MMP-
based collagen turnover in the ECM205. The combination of the anabolic effect and increased 
turnover due to the training alongside to the ECM remodeling set the basis of justifying TNNT1 
levels as well. At this point unfortunately, it is not feasible to define a precise origin for the 
biomarker changes.  
 
6.2. 2. TNNT1 serum levels in disuse induced muscle loss (Berlin Bed rest study, 
BBR) 
 
Measurements of muscle mass determined by DEXA and MRI have demonstrated the extent of 
muscle loss caused by disuse in prolonged periods of bed-rest 206. In prolonged inactivity there 
is also a higher degradation rate of slow-twitch muscle fibers as verified in animal and human 
studies 17,207. It is important to find possible counter measures and many regimes are have been 
studied, regarding their ability to prevent or reverse it muscle 208,209.  Resistance vibration 
exercise (RVE) is one of the methods proposed for countering the muscle loss. RVE is an 
eccentric form of exercise, meaning that at the time of force generation the muscle is in 
lengthening state. A common example of eccentric contraction occurs when running downhill. 
As the leg stretches to meet the ground, the muscle goes under load and generates force, 
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performing an eccentric contraction.  It is documented that eccentric training is related to 
muscle injury and fiber type preferential damage, leading to release of protein fragments, 
including troponins, in blood circulation 200,210,211. Studies have shown that although eccentric 
exercise leads to pronounced damage of muscle fibers, it also end in a greater hypertrophy, 
showing the complexity of muscle anabolism. In our hypothesis of testing the levels of TNNT1 
in a longitudinal bed rest study with and without counter-treatment, we expected to find 
changes both between the two groups and between the different time points.  
Interestingly, we have observed that at the initial stage of bed rest there was a different 
unloading process in the control (CTRL) group compared to the RVE. The difference was most 
pronounced in the fifth day of bed rest (BR5 CTRL vs RVE, p=0.0002). The initial drop could be 
possibly explained by the absence of any activity of the lower extremities, affecting normal 
degradation of protein as measured at the baseline. During the following days, it could be that 
atrophy ensues due to disuse and the turnover balance leans to muscle degradation. Similarly 
to the BBR study we used206 Salanova et al have demonstrated the changes in the muscle fiber 
composition and protein contents in a very similar study named BBR2212. Participants were 
divided into three groups that had RVE training, resistance training or no counter measures and 
biopsies from soleus and VL muscles were obtained at baseline and after 60 days of bed rest. 
According to their findings, there was a decrease in the size of type I fibers in the CTRL group 
for both SOL and VL, while the RVE group maintained fiber size. Additionally, there was a clear 
drop in the total number of type I fibers between the two biopsies for the CTRL group while in 
the RVE the negative change was not as pronounced. These findings are in agreement of 
previous studies showing a favoritism of type II fiber wasting in eccentric training201.  However, 
based on 2D DIGE quantification, TNNT1 specifically was found in lower levels in the end 
biopsies of both muscles for the RVE group, while for the CTRL group it was increased in SOL 
but decreased in VL. These data could explain the release of TNNT1 in circulation for the RVE 
group even when type I fiber wasting was not as not as marked as the CTRL group.  Repeated 
bouts of eccentric contractions under RVE training may be a confounding parameter for the 
elevated increase of TNNT1. In the CTRL group, within the type I-rich SOL muscle the levels of 
TNNT1 were increased but were decreased in VL. This differential expression between the 
miscellaneous leg muscles in the CTRL group could be the reason for the variable pattern before 
the recovery stage.  
During the remobilization stage, very similar release kinetics were observed in the two groups 
for the TNNT1 levels. As participants were regaining muscle, a steady elevation of TNNT1 was 
observed and peaked on day 28 of the recovery as it can be seen in fig 4 in manuscript III.  Upon 
completion of the study period, TNNT1 levels were almost back to normal. This could reflect a 
systemic response triggered by training. Various publications support the skeletal troponin 
release during training201,213. In previous publications regarding the BBR study, collagen and 
titin biomarkers were also investigated155,188. Collagen III formation biomarker (Pro-C3) has 
demonstrated direct correlation with changes in LBM. The release pattern during the bed rest 
was very similar to TNNT1 in the control group, possibly indicating a close relation to the release 
of the TNNT1 and changes to the LBM. The MMP-2 cleaved titin biomarker also followed the 
same initial decrease as TNNT1, depicting the disuse-induced initial atrophy.  
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Within the confines of the study setting, it is difficult to be absolute on what is the cause for 
the release of TNNT1 in both the immobilization and reloading period. There is no clear 
anabolic or catabolic stimulus and in some cases, the possibility for this could be masked by 
changes due to damage from eccentric exercise. In catabolic conditions, caspase-3 has been 
found to be activated in skeletal muscle, assisting to the degradation through the ubiquitin-
proteasome system214. TnT is found to be a substrate of caspase-3 with a distinct fragmentation 
site observed in cardiomyopathy studies 215. The cleavage site is conserved in the slow skeletal 
isoform, which could be one of the possible ways that TNNT1 is detached from the protein 
complex. When conformational changes during muscle contraction and relaxation occur in the 
troponin system, lower association to the TNNT1 could set it free. We have established that 
truncation of the C-terminus of TnT leads to inability of complete muscle relaxation which can 
be associated to poor grip strength. It would be very interesting to test if progressive 
accumulation of TNNT1 in patients of muscle wasting can also correlate to changes in grip 
strength.  
 
[80] 
 
7. LIMITATIONS  
There are several limitations to our findings that need to be taken into account when 
interpreting the results. All of the studies are relatively small and are more likely to serve as 
proof of concept rather that undisputed evidence. Furthermore, no information was obtained 
regarding collagen deposition and fibrosis within the muscle tissue. Fibrosis could directly affect 
the ECM fingerprint measurements in the myositis study, but also affect muscle regeneration 
capacity during training.  
 
In the myositis study, it would be of relevance to have  MMT8 scores in the age- and gender 
matched controls. This would allow verifying that differences between the patient groups and 
controls  are related specifically to their pathologies and not a random intrinsic trait of the 
biomarkers. Furthermore, although the MMT8 has previously demonstrated good test-retest 
reliability in the hands of experienced raters across the various items, no reliability 
measurement of the MMT8 raters was performed in this study. It must be considered that 
MMT8 is affected by structural damage, loss of muscle tissue but also pain when it 
compromises movement. In many of the other papers in the literature about myositis 
biomarkers besides MMT8, correlations between biomarkers with pain scores in the form of 
muscle VAS were included 193,196. Unfortunately, in this study, we did not have access to muscle 
VAS scores. However, the muscle VAS score is also a subjective score with reliability in the same 
range as the MMT8 score. Finally, we did not take into account the potential effect of the 
glucocorticoid and/or baseline methotrexate therapy, although a previous study showed that 
the IFN score was unaffected by this183. Future assessments of the biomarker panel in myositis 
studies required.  
 
Regarding the BBR study, despite the similarities with the results obtained from 2D gels from 
other studies, it needs to be kept in mind that those assays do not measure exactly the same 
thing. In the gel system, only the full protein can be identified while our assay targets the C-
terminal part of TNNT1, which would indiscreetly measure the whole protein and/or any 
fragments that would include the epitope.  
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8. CONCLUSION  
 
In this thesis, we have demonstrated the needs for novel biomarkers in the field of skeletal 
muscle pathologies. Protein biomarkers in serum are easily obtainable, not as invasive as other 
methods and can be used as targets for antibody-based assays. We have tested biomarkers 
targeting both intracellular and extracellular proteins in muscle. We have found differential 
regulation of those markers between pathological and healthy groups as well as correlations to 
strength and function outputs.  
To further specify, we found that: 
 
 
(1) It is possible to use ECM based neo-epitopes and inflammatory biomarkers to distinguish 
between (a) populations suffering from different inflammatory myopathies and (b) a 
control group of healthy individuals. (manuscript II) 
(2) ECM based and inflammatory biomarkers are able to mirror changes in functionality, 
force generation and disease activity in inflammatory myopathy patients. (manuscript II) 
(3) TNNT1 is a good biomarker candidate, able to be released and detected in blood 
circulation under muscle damage in a distinct manner directed by the pathology. 
(manuscript III) 
(4) It is unclear whether TNNT1 can follow the catabolic/anabolic effects induced by the 
disuse model and the training intervention in either study. However, there is evidence 
that TNNT1 follows fiber-type preferential wasting trends as it should and a possible 
mechanism for the release was discussed. (manuscript III) 
 
 
The results of this thesis verify that a panel of biomarkers could fill in the need to characterize 
complex processes in rare neuromuscular diseases. Addressing the main manifestation of the 
diseases in well-described clinical cohorts could expedite pharmaceutical trials and provide 
valuable information on the pathology of the disease. Indeed, based on these findings, 
biomarker panels consisting of ELISAs against Collagen type I and III fragments and MMP-
degraded CRP are promising biomarkers in myositis in terms of diagnosis, functional 
characterization and likely monitoring of treatment efficacy. Being able to recognize subtle 
differences between DM and PM is a valuable asset, as it is attractive to treat the two forms of 
myositis with different regimens. Since there is a lot of variation in the different forms of 
myopathies and dystrophies, the use of non-invasive serum biomarkers possibly assist in 
personalized care in the future.  
 
Having biomarkers that have proven to describe the individual symptoms of inflammation, 
fibrosis and muscle wasting could also assist in developing other biomarkers. Since dystrophies 
are very rare diseases, it is hard to get access to large, well-planned cohorts to test potential 
biomarkers. Cell and animal-based models are usually employed but do not behave the same 
as the in vivo processes in human. Using pathological models in human studies that are at the 
same time clinically described through such biomarkers can generate data that will appealing 
enough to argue for the use of the biomarkers in the big cohorts.  
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Besides underlining the importance of the ECM in muscle pathologies, we also addressed the 
potential of intramuscular proteins to be used as biomarkers. Targeting the C-terminus of 
Troponin T1, we have developed a robust and specific biomarker assay. Although we could not 
verify the mechanisms that TNNT1 reflects regarding the protein turnover, it has been shown 
promising results. In order to improve the ability of the biomarker to demonstrate specific 
response in molecular pathways of wasting, it could be implemented in a neo-epitope assay. 
We already know that there is a conserved cleavage point for caspase-3 in skeletal TnT and that 
caspase-3 activation has biological significance in muscle pathologies. A sandwich ELISA could 
be developed targeting the caspase-3 cleavage site on the one end and the skeletal specific 
TNNT1 site on the other end. This approach would ensure that only fragments from skeletal 
muscle that have been affected by a very specific pathway are detected. It would be very 
interesting to see if such a setup would elucidate the involvement of TNNT1 in muscle 
pathologies. 
 As fragmentation in the c-terminus of TnT has an impact on the proper muscle contraction and 
force generation it would be very interesting to test TNNT1 in study that is directed at changes 
in force generation and proper relaxation. A very relevant disease for TNNT1 to be tested for 
its clinical significance, could by myotonic dystrophy which has a unique pathology associated 
with general stiffness and difficulties in relaxation of grip 216. In addition to signs of possible 
dysregulation of the troponin system, myotonic dystrophy has also demonstrate profound 
selective atrophy of type I muscle fibers and isotype shifting.  
 
Future perspectives 
 
Despite these encouraging preliminary data, the cohorts that were used, were multivariate in 
regarding the changes in muscle. The biomarkers seem promising but will be much better 
characterized, if applied to simpler cohorts. For example a study with young men with and 
without anabolic stimulus (drug and/or training induced) would be a way to determine if the 
biomarkers respond to the anabolic conditions.  It is also of our great interest to measure all 
the relevant protein fingerprint biomarkers in a big cohort of the most common dystrophies. 
Despite cross sectional studies being already interesting, a prospective study with different 
time points under a possible treatment including relevant primary and secondary outcomes 
(function tests, strength tests, LBM assessment etc.) would be the ideal cohort. Furthermore, 
a key area that we did not manage to test our biomarkers is regarding intramuscular fibrosis. 
The ECM has a paramount role in many of the dystrophies and a biomarker panel as the 
collagen fingerprint could give early insight on changes after treatment or other therapeutic 
intervention. This would give a well-rounded picture of the actual potential of protein 
fingerprint panels in neuromuscular disorders and help propel drug discovery.  
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